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FHIT   : Fragile Histidine Triad Protein 
FISH              : Flourescent In situ Hybridisation 
Fn 14            : Fibroblast Growth factor Inducible Factor 14 
GERD            : Gastro esophageal reflux disease. 
GFAP           : Glial Fibrillary Acidic Protein 
GIT              :Gastro intestinal Tract 
H.Pylori       : Helicobactor pylori 
HBEGF       : Heparin Binding Epidermal Growth Factor 
HCG            : Human Chorionic Gonadotropin 
HER 2          : Human Epidermal Growth Factor Receptor 
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MALDI        : Matrix assisted laser desorption/ Ionisation mass spectrometry 
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MAPK            : Mitogen Activated  Protein Kinase 
MMP               : Matrix Metalloproteinase 
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mTOR             : Mammalian Target of Rapamycin 
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NEC             : Neuro Endocrine Carcinoma 
NET             : Neuro Endocrine Tumour 
NF-κB             : Nuclear Factor kappa –B 
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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
Gastric carcinomas rank among the top five devastating cancers of the world. They 
constitute 6.8% of the total cancer cases diagnosed every year 1.   World cancer statistics ranked 
it third in cancer related mortality. It results in nearly 0.7 million deaths annually 1. 
 The Chennai cancer registry statistics states gastric carcinoma as the most common 
cancer in males. It constitutes 10.2% of all cancer cases in men. It is the third most common 
cancer among females constituting 4.69% 2.The incidence rate is more in males when compared 
to females. People in their fifth to sixth decade are commonly affected 2. 
 In the forthcoming decade gastric carcinoma would be the major killer disease. In India 
gastric cancer related mortality would raise upto 19.8% 3. In spite of its magnitude gastric 
carcinomas have a wide geographic variability. Asians have increased incidence rate when 
compared to Caucasians and Africans.4, 5 
 Risk factors include H.pylori infections, diet, alcohol, tobacco and blood group ‘A’. 
Medical conditions like menetrier’s disease, gastric adenomas. Pernicious anaemia contribute to 
risk.4, 6, 7, 8  
        The most common site for the occurrence of gastric carcinoma is the distal end of the 
stomach. Recently increased incidence of carcinoma in the proximal end has been reported.7, 
Gastric carcinomas lack specific symptoms in its early stage delaying timely diagnosis. 
These results in advanced stage of illness that has poor curability rates 4.The most commonly 
used diagnostic tool is the endoscopic guided biopsies .But they tend to miss out a considerable 
number of cases 4. 
 Majority of the gastric carcinomas are adenocarcinomas. Other variants are 
adenosquamous, neuroendocrine, mesenchymal tumours and lymphomas.9 
 Conventionally the prognosis of gastric carcinoma depends upon the TNM staging. This 
includes depth of invasion, nodal status and distant metastasis.  Latest research works discovered 
special proteins expressed by the tumour cells. These proteins play a significant role in 
determining the prognosis. 10, 11, 12 
 In this study carried out in Thanjavur medical college the histopathological analysis along 
with the immunohistochemical expression of two markers namely HER2 neu and Ki-67 were 
studied. 
 Ki-67 is a proliferation marker. It is related to the degree of differentiation, infiltration 
and lymph node metastasis. 12 
 HER2 neu belongs to the family of epidermal growth factor receptors. It is overexpressed 
in a number of carcinomas. Its overexpression in gastric carcinomas is associated with more 
aggressive disease.10, 11, 13 
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AIMS AND OBJECTIVES 
 
1. To study the incidence of gastric carcinomas reported in the department of pathology , 
Thanjavur medical college 
2. To determine the age and sex wise distribution of gastric carcinomas of various 
histological types. 
3. To analyse the anatomical distribution of gastric carcinomas. 
4. To evaluate the expression of Ki-67 and HER 2 neu in gastric carcinomas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
 A total of 260 specimens including endoscopic biopsies and gastrectomy specimens 
received in the department of Pathology, Thanjavur medical college during the period of July 
2012 to June 2014 from the department of gastroenterology and Surgery were included in this 
study. 
EXCLUSION CRITERIA 
1. Chronic gastritis 
2. Lesions in OG junction or in its proximal 5 cm 
3. Nil tissue 
4. Few dysplastic cells 
5. Non neoplastic polyps 
6. Ulcers with inflammation 
 
The case details including the age and sex were recorded for all cases. Depending on the site of 
lesion, the stomach is dissected. It was opened either along the greater curvature or the lesser 
curvature. The specimen was pinned with its mucosal side up. It was fixed in 10% buffered 
formalin overnight. The specimen was then measured along its lesser and greater curvature. Any 
abnormal lesion such as ulcer, growth, flattening of mucosa was noted. Size, colour, shape, 
consistency, margins of ulcer, location, perforation if any, relation to the resected margins, 
relation to the visceral peritoneum was noted. The adjacent mucosa was examined for any gross 
abnormalities. The lesion was then cross sectioned to examine the depth of invasion 6,14.  
 
 
SECTIONS FOR HISTOLOGY  
1. Tumor proper – four sections through the wall including tumour border and adjacent 
mucosa 
2. Non neoplastic mucosa in mid stomach – two sections 
3. Proximal line of resection along the lesser curvature – two sections 
4. Proximal line of resection along the greater curvature – two sections 
5. Distal line of resection ( along pylorus and duodenum if present ) – two sections 
6. Spleen if present 
7. Pancreas if present 
8. Lymph nodes – along the pylorus, lesser and greater curvature , perisplenic and omental 
nodes 
                         The bits were subjected to routine tissue processing and paraffin embedding. 
Three to four micrometer sections were cut. The sections were stained with hematoxylin and 
eosin.(Appendix I). Entire gastric wall was visualized and the depth of invasion was determined. 
The sections were studied and histopathological parameters were evaluated according to the 
WHO classification criteria. Histochemistry was done with PAS stain to demonstrate the signet 
ring cells, in Carcinomas ( Appendix II) 
    The immunohistochemical study was done using monoclonal primary antibody. They were 
directed against HER2 cytoplasmic membrane antigen and Ki-67 nuclear antigen. Sections of 4 
micrometer thickness were used. The super sensitive TM polymer – HRP detection system was 
employed. It uses a non biotin polymeric technology. Here secondary antibody conjugated to 
poly-HRP reagent was bound to primary antibody. It can be visualized by DAB chromogen. 
(Appendix III) 
 
HER 2 STAINING 15 
 
Grade 
Surgical specimen Staining 
pattern 
Biopsy specimen 
staining pattern 
Her 2 Over 
expression 
assessment 
0 
No reactivity ( or ) 
Membranous reactivity in 
<10% tumour cells 
No reactivity in any tumour cell 
Negative 
1 + 
Faint or barely perceptible 
membranous reactivity in 10 
% or more cells ; cells are 
reactive only in part of their 
membranes 
Tumour cell cluster a  with faint or 
barely perceptible membranous 
reactivity irrespective of % of tumour 
cells stained 
Negative 
2 + 
Weak to moderate complete 
basolateral or lateral 
membranous reactivity in 
10% or more of tumour cells 
Tumour cell cluster with weak to 
moderate complete, basolateral or 
lateral membranous activity 
irrespective of % of tumour cells 
stained 
Equivocal 
3 + 
Strong complete lateral or 
basolateral membranous 
reactivity in 10% or more of 
tumour cells 
Tumour cell cluster with strong 
complete lateral or basolateral 
membranous reactivity irrespective of 
% of tumour cells stained 
Positive 
a - Tumour cell cluster is defined as cluster of five or more tumour cells 
 
 
Ki-67 Immunostaining 
 
 The conventional four micrometer sections are cut from paraffin block. 
Immunohistochemical staining procedure is performed using the heat induced antigen retrival. 
Specific Murine Monoclonal Antibody – MIB-1 is used. Labeling Index is measured as 
percentage of MIB-1 positive cells in 1000 randomly selected tumour cells. The strong brown 
nuclear staining is considered positive. Weak nuclear or cytoplasmic staining is considered 
negative. 
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REVIEW OF LITERATURE 
 
“Growth For The Sake Of Growth Is The Ideology Of The Cancer Cell” 
-Edward Abbey (1927 -1989) 
 American author and essayist 
 
                           Popularly known  as “captain of men of death” gastric carcinoma has its 
association with mankind from time immemorial. 
 
Historical aspects 16   
 Cases resembling gastric cancer were first reported in the Ebers papyrus in 1600 BC 
  Gastric cancer was mentioned in the reports of Hippocrates in the 2nd century AD in 
Rome. 
 A condition resembling gastric cancer was described in Avicenna’s medical encyclopedia 
in the 11th century. 
 Benign and malignant gastric ulcer were described in 1835 by J.Cruveilhier. 
 The death of Emperor Napoleon Bonaparte in 1821 was attributed to extensive scirrhous 
carcinoma of stomach . This was concluded based on the post mortem findings. 
 The first gastric resection for cancer was performed by Jules Emilen Pean, a French 
surgeon in 1879. 
 The first subtotal gastric resection with gastroduodenal anastamosis was performed in 
1881 by Theodor Billroth. 
 The first total gastrectomy was performed by Karl Schlatter in 1897. 
Embryology 17 
 During the fourth week of development stomach begins to form. It starts as a fusiform 
dilatation of foregut. It rotates 90º in its longitudinal axis. Hence making its left side lie 
anteriorly and right side lie posteriorly. There is rapid growth of posterior wall when compared 
to anterior wall. This results in the formation of lesser and greater curvature. Further rotation of 
the stomach along its anteroposterior axis occurs. Resulting in the caudal end moving towards 
the right and  upwards. Cephalic portion to move towards  the left and slightly downwards. This 
results in the final position of the stomach. 
Anatomy 18, 19 
 The stomach is situated in the upper abdomen. It extends from left upper quadrant, 
downwards forwards and to the right. It further extends towards the left hypochondriac, 
epigastric and umbilical areas. 
Average capacity of the  stomach at birth and at puberty 30 and 1000 ml respectively. 
Adult stomach has a capacity of 1500 ml. 
           The dome shaped fundus projects above and to left of cardiac orifice. It extends above 
the line drawn from incisura cardia to greater curvature. 
The body of the stomach extends from the fundus to the incisura angularis. It is a notch in 
the lower end of lesser curvature. The lower boundary of the body of stomach is the line drawn 
from the incisura angularis to an indentation on the greater curvature. The position of the incisura 
angularis varies with gastric distension. 
The pyloric antrum extends from lower boundary of body to sulcus intermedius. From 
here stomach narrows to form the pyloric canal. Pyloric canal measures around is 1-2 cm in 
length. The pyloric orifice is formed by marked thickening of circular muscular layer. Some 
fibres of longitudinal muscle coat also form pyloric antrum. 
Lesser curvature gives attachment to lesser omentum. It contains right and left gastric 
vessels. Greater curvature gives attachment to the greater omentum. This contains gastroepiploic 
vessels and gastrosplenic ligaments. 
      Fundic mucosa extends into abdominal esophagus in a zigzag pattern forming Z line. The 
esophageal epithelium lies above this Z line. Z line is considered to be the gastroesophageal 
junction for histology and endoscopy. 
The medial wall of stomach has the cardiac orifice. Its thickened mucosa forms a 
mucosal rosette that lines the orifice. Mucosa of fundus is thrown into gentle folds with no 
particular pattern. The body has more prominent mucosal folds. They appear as long broad 
ridges running from fundus to pyloric antrum. The magenstrasse are the least prominent 
smoother folds on the medial surface. They direct the liquid entering the stomach directly on the 
pyloric antrum. The antrum has a smooth mucosal surface. This culminates with puckering of the 
mucosa at the pyloric orifice. 
Blood supply 19 
  Celiac trunk, its branches hepatic and splenic arteries constitute the major blood supply. 
 The venous drainage of the stomach is divided into two portions. The proximal part 
drains into inferior esophageal plexus. The distal part drains into the portal vein. 
  Parasympathetic innervation is via the branches of vagus connecting Meissner and 
Auerbach plexus. The sympathetic innervations are via the celiac plexus.  
The lymph nodes draining the stomach are numerous.  They are right and left subpyloric, 
paracardial, splenopancreatic and gastroepiploic nodes. 
HISTOLOGY 19, 20 
 
 
MUCOSA 
 Gastric mucosa is composed of a superficial layer and deep layer. The superficial layer is 
composed of foveolae or pits. They are formed due to invagination of surface epithelium. The 
deep layer is composed mainly of coiled glands. These glands empty in the base of foveolae. 
Glands in cardiac mucosa and proximal end of pyloric mucosa secrete mucus. 
Surface Epithelium 
 The gastric mucosa is lined by mucus secreting tall columnar cells. They line the surface 
and the foveolae. The gastric glands are separated from the foveolae by the lamina propria.  
Foveolae in cardiac and pyloric end are wider imparting a villous architecture .The lining cells 
are tall columnar with a basally located nuclei. Nucleus is characterized by evenly distributed 
chromatin and inconspicuous nucleoli. The cytoplasm is superficial in location and filled with 
mucus. 
Cardiac & Pyloric Mucosa 
 Half of the mucosal thickness is occupied by the foveolae. The glands are mucus 
secreting and loosely packed. Parietal cells are found in isolated small clusters at the pyloric 
region. Pyloric glands secrete only neutral mucin. Cardiac glands secrete both neutral mucin and 
sialomucin. 
 Cardiac mucosal abnormalities arise in setting of H.pylori infection or GERD. This 
results in inflammatory nuclear atypia, intestinal metaplasia and a hybrid mucosa. Hybrid 
mucosa is multilayered with surface columnar epithelium and basal squamous cell. 
 
 
 
 
Fundic Mucosa 
 Fundic mucosa is also known as the Oxyntic mucosa. The foveola occupies less than ¼ th 
of the mucosal thickness. The glands are straight and tightly packed. They are divided into three 
portions 
Base – Composed of zymogenic cells. They are cuboidal cells with pale blue gray cytoplasm. 
They have a basally situated nucleus and a small nucleolus. 
Isthmus - composed of triangular parietal cells with their base lying on basement membrane. 
They have an eosinophilic cytoplasm and a centrally placed nucleus. 
Neck – composed predominantly of a mixture of zymogenic and parietal cells. These cells are 
admixed with mucous neck cells. 
Endocrine cells in stomach 
 Hormones from endocrine cells enter blood directly or exert a paracrine effect. 
        Antrum -  50 % - Gastrin producing G cells 
  30% - Enterochromaffin cells 
  15% - D cells 
      Fundus – Predominantly enterochromaffin like cells 
  X cells. 
  Enterochromaffin cells. 
Lamina propria 
 It provides structural support. Composed of framework of reticulin, collagen and elastic 
fibres. Also contain cells like fibroblasts, histiocytes, plasma cells and lymphocytes. It also 
contains capillaries, arterioles and non myelinated nerve fibres. Occasional lymphocytes and 
plasma cells of B cell lineage may be found. They secrete IgA antibodies. 
 
Muscularis Mucosa 
 They are composed of inner circular and outer longitudinal smooth muscle bundles. 
These muscle fibres are admixed with some elastin fibres. They are most obvious in antrum. 
Submucosa 
  Core of gastric rugae is composed of submucosa, loose connective tissue, elastic fibres. 
They also contain autonomic nerve plexus of meissner, veins, arteries and lymphatics. 
Muscularis Propria 
 Composed of outer longitudinal, inner circular and innermost oblique smooth muscle 
fibres. The fibres in outer longitudinal layer are continuous with the longitudinal layer of 
esophagus. The pyloric sphincter is formed by the aggregation of fibres of inner circular layer. 
The oblique layer is incomplete and is appreciable only in the cardia. The muscularis propria is 
thicker in the pyloric antrum. 
Subserosa 
  Subserosal region has small blood vessels, fat cells and inconspicuous mesothelial cells. 
Serosa 
 The gastric serosa is continuous with the greater and lesser omentum. 
 
CELLS OF GASTRIC EPITHELIUM 
Chief cells 
 Cuboidal cell with round euchromatic nucleus, basophilic cytoplasm and  secretory 
zymogen granules. The chief cells secrete digestive enzymes pepsin and lipase. They are situated 
in the basal portion of the glands.  
 
 
Parietal cells / Oxyntic cells 
  Large eosinophilic cell with a centrally placed nucleus. They secrete gastric acid and 
intrinsic factor and have a unique ultrastructural feature. Their luminal side is invaginated by 
blind ended channels with numerous microvilli. These microvillus contain H+/K+ atpase anti-
porter channels. They secrete hydrogen ions into the lumen. The mitochondria rich cytoplasm 
contains tubule vesicular system. 
Mucus Neck Cells 
 They are numerous at the neck and at the basal regions. It has mucin containing apical 
secretory vesicles. 
Stem cells 
 They are located in the neck of gastric glands. Some are also located in the base of gastric 
pits. Not normally identified after damage to the gastric mucosa. 
Neuroendocrine cells 
 They occur in the body and fundus among chief cells. These cells contain a basally 
situated irregular nuclei and granular cytoplasm. Cytoplasmic secretory granules are essential for 
gut motility and glandular secretion. 
 
Functions Of Stomach 
 Fundus - Act as a pacemaker for co-ordinated contraction 
 Cardia   - Helps in propulsion 
 Antrum - Crushing and grinding function 
 
 
 
SPECIAL STAINS19 
 Giemsa stain highlights mast cells, H.Pylori, Giardia, Cryptosporidium. H.pylori is also 
demonstrated using warthin starry stain or the Steiner modified silver technique. Fungus is 
demonstrated using PAS after diastase application or methanamine silver technique. 
 The neutral mucins are better demonstrated with PAS with diastase. Acid sialomucin are 
demonstrated with Meyers mucicarmine and alcian blue at ph 2.5. 
 The sulphated mucin can be demonstrated by high iron diamine (HID) stain or alcian blue 
at pH of 1. 
Endocrine cells 
Argentaffin –  Masson Fontana 
Argyrophilic - 1. Grimelius 
  2. Churukian. 
  3. Schenk. 
 
ENDOSCOPIC EXAMINATION and BIOPSY 7,19,20 
 Endoscopy is often the first line investigations in gastritis and gastric ulcer.It helps in 
diagnosis and in also management of ulcer.In addition to diagnosis it helps in monitoring cases 
following therapy and  complications. 
 Endoscopic surveillance is used for screening in  high incidence areas of gastric 
carcinoma. Japanese employ a technique of applying dyes like Toluidine blue or congored. It 
distinguishes between normal and dysplastic gastric mucosa. 
 Endoscopy helps in sampling the lesion. It  provides information regarding colour, 
texture and degree of vascularity of  mucosa. 
EPIDEMIOLOGY 5, 21,22,23 
 
 
 
  Gastric carcinoma is the fourth most common cancer in the world. It is the second 
leading cause of cancer mortality. Inspite of its magnitude its incidence varies in different parts 
of world. Its predominant in developing countries when compared to developed western 
countries. 
  The occurrence of gastric carcinoma peaks in the sixth to seventh decade. It is 
uncommon in the younger individuals. 
  Recently there is an increasing incidence of gastric carcinoma in the proximal 
stomach. They are distinct from conventional tumours with more incidence in younger age. It is 
associated with conditions like hiatal hernia and GERD. They are less commonly influenced by 
ethnicity, diet or  family history. 
  In spite of the number of diagnostic modalities gastric cancer mortality remains 
high. Most of the gastric cancers remain undetected in the early stage. Paucity of clinical 
symptoms  delays  diagnosis  resulting in significant morbidity and mortality. 
 
Risk Factors 7,8 
  According to the International Agency for Research on Cancer (IARC) the risk 
factor for gastric carcinoma has been broadly categorised into  
Factors with convincing evidence for increased risk 
  H.pylori infection, tobacco chewing, X rays, Gamma rays and working in rubber 
factories 
 
 
Factor with probable evidence 
 Nitrate or nitrites, pickled vegetables, salted fish,salty foods, Asbestos, Inorganic lead 
compounds, Epstein barr virus. 
 
Helicobacter pylori infection 
  Considerable cases of gastric adenocarcinoma is associated with multifocal atrophic 
gastritis. This is mainly due to H.pylori infection. H.pylori is not directly carcinogenic it aids 
tumorigenesis. It acts by 
1) Intestinal metaplasia,  
2) Cag A or Vac A positive strains of H.Pylori causes uncontrolled cell proliferation or 
apoptosis. 
3)  Hypochlorhydria resulting from atrophic gastritis results in overgrowth of anaerobic 
bacteria.This converts reactive nitrate intermediates into carcinogenic substances. 
4) The reactive oxygen species are released during inflammation.They damage lipids, 
DNA ,proteins and oxidises antioxidants like vitamin C. 
Individuals with HLA-DQA1*0102 genotype are resistant to H.pylori induced intestinal        
metaplasia and are at decreased risk for gastric adenocarcinoma 
Dietary factors 
 Soyabean products  consumed in Asia combined with sodium nitrite is  mutagenic. Salty 
food damages  gastric mucosa and enhances cell proliferation. Consumption of processed meat 
enhances the risk of gastric carcinoma. Consumption of fresh fruits and vegetables decreases the 
risk of carcinoma. Tobacco is a proven risk factor. Carcinogenic potential of alcohol in causing 
gastric carcinoma is not clearly evident. 
Influence of dietary factors in gastric carcinoma in India35,36,37,38  
 
               Diverse ethinicity and cultural variation in India reflects in local cusine. This 
plays a major role in determing the risk of gastric carcinoma. Incidence of gatric carcinoma is 
high in the southern parts of india. South Indians are more affected compared to the population 
in the north. 
               Low intake of fresh fruits and high prevalance of smoking and alcoholism are 
important determinants of stomach cancer in the rural population of India.According to  Imran et. 
al.35 High cooking temperature of Indian dishes destroys vitamin C. This decreases protective 
anti oxidant effect. Cancer incidence is high in north eastern states of India like Sikkim, 
Arunachal pradesh and Nagaland. Increased consumption of smoked meat increses the risk.  
Tuibur, a local beverage which is a filterate of tobacco in water increases the risk of gastric 
carcinoma. 
                          Increased intake of brassica vegetables, chillis and salted tea in kashmiris 
increases the risk. This increases content of dietary amines and carcinogenic nitrocompounds. 
Drinking tea is said to have a protective effect on gatric mucosa. Increased consumption of 
coffee increased the chance of acquiring gastric carcinoma by 20%. But this data is not 
statistically proven. 
                Intestinal type of adenocarcinoma is commonly associated with smoking. 
Consumption of tobacco and smoking comes in various forms. Bidi is a local cigar produced 
from sun cured leaves of tobacco.It is rolled in sheets of dried temburni leaves (Diospyros 
melanoxylon). It has a nicotine content of roughly 0.2 – 0.3 gm3. Chutta or cheeroot is a smaller 
form of cigar .It is made by rolling tobacco flakes in sun dried tobacco leaf. Snuff is an inhalent 
form of tobacco.This comes in the form of a fine dried powder. Quid is the chewable product 
made from vine piper betal. It is chewed with bits of areca nut and small amount of lime. Hookah 
smoking is a traditional form of smoking practised in kashmir. This is a mixture of tobacco 
leaves, honey and other local fruits . Habitual hookah smoking is associated with increased risk 
of developing cancer.  
   Increased risk of gastric carcinoma is seen among smokers of bidi. The content of 
tobacco is less in bidi when compared to cigars.  Tar, benzene compounds and hydrocarbons are 
carcinogenic. Decresed Porosity of the Leaf, low combustibility and high Concentration Of 
Volatile Phenols increase the risk. 
                     A variety of liquors are cosumed in India. Toddy  is the fermented palm sap 
produced locally. Arrack is a locally brewed liquor with 40% ethanol content. Other drinks are 
wine, whiskey, beer, brandy,gin and rum.  Increased risk of gastric carcinoma is associated with 
increased arrack consumption. Risk of gastric carcinoma is  increased  with consumption of 
Vodka and red wine. 
                          Nagaraj et al states that in a study carried out in Tata memorial hospital it has 
been conclude that consumption of wine increases the risk of development of carcinoma when 
compared to individuals who consume beer, brandy, rum and tequila. 
               Increased intake of fruits and vegetables has  negative corelation to  occurance of 
gastric carcinoma.  The high levels of antioxidants  protects gastric mucosa by inhibiting the 
nitration process. Vegetables and meat that has been salted ,pickled or smoked are carcinogenic. 
They act as abarasives in gastric mucosa elevating the levels of nitrosocompounds. Foods like 
allium, garlic, onion, green tea  protects gastric mucosa. Individuals with pernicious anaemia has 
increased tendency to develop papillary lesions of stomach.Nagaraj et al  states that increased 
consumption of dried fish increases  the risk of gatric carcinoma.  
Occupational risk 
                          In a study carried out in Australia occupational risks were analysed. Subset of 
population who practice  agriculture  have decreased risk for developing carcinoma. Individuals  
occupied in news printing have increased due to lead exposure. Increased risk is present in 
grinder operators exposed to mineral oil & ethanolamine. Individuals involved  in electrical and 
electronics industry, pavers and excavators  have increased risk. 
 
GENETIC FACTORS 23,24,6,26 
 
Genetics of gastric carcinoma6,23,24,26 
             12% of gases of gastric carcinoma show familial inheritance. The most popular 
example is  Emperor Napolean Bonaparte and his family members .They were believed to have 
succumbed to  schirrous variant of gastric carcinoma. 
                 Swedish Family cancer database documents the standerdised incidence ratio in a 
child whose parent was affected by gastric carcinoma as 1.59. In case of a sibiling it is 5.75%. 
This implies that  risk in sibilings is higher when compared to offsprings. 
Inherited predisposition syndromes 
           1-3% of all cases of gastric carcinoma come under this category. 
Heriditary diffuse gastric cancer  
Cases of gastric carcinoma with an autosomal pattern of inheritance and high penetrance 
was observed in tha Maori families Linkage Analysis Was Performed. It revealed mutations in  
E-Cadherin/CDH locus on long arm of chromosome 16 at position 22. Till date multiple E-
Cadherin mutations has been noted. These mutations are found distributed among nearly 16 
exons. 70% of them being truncated mutations and 30% are missense mutations.  Age of onset 
ranges from 15 to 70 yrs with an average age of around 40 years. Females with this mutation has 
an 60% increased risk of acquiring lobular carcinoma of breast. They are prone to develop the 
tumour  before 80 years of age.  Incomplete penetrance in mutation of this kind does not seem to 
produce carcinoma.  Prophylactic gastrectomy and rigorous surveillance of breast cancer is 
recommended. Individuals harbouring E Cadherin mutations should be screened  from 20 years 
of age. 
1. Lynch syndrome 
This occurs due to a mutation in germline mismatch repair gene. Usually produces 
intestinal typeof adenocarcinoma with no evidence of H.pylori infection. The mean age of 
occurance is 56 years 
 
2. Li Fraumeni syndrome 
It is charecterised by occurance of multiple tumours. They include sarcomas, carcinoma 
breast, CNS tumours, leukemias, gastric carcinomas and adrenocaortical tumours. This is 
attributed to germline mutation in P53. 
3.Peutz Jeghers Syndrome 
It is caused by germline mutation in STK11.It is an autosomal dominant disorder. 
Charecterised by pigmentation of digits,lips,buccal mucosa, hamartomatous polyps and 
carcinomas of gastrointestinal tract.  
Gastric carcinomas are also part of the Juvenile polyposis syndrome in individuals who 
harbour mutations in SMAD 4 or BMPR11A. 
 
Genetic alterations in gastric cancer 
Gastric mucosa is composed of numerous multipotent stem cells that forming clonal 
units. The crypts showing intestinal metaplasia showed clonality. They are composed of multiple 
pluripotent stem cells that spread by crypt fission.  Frameshift mutation in TGFβ II, IGF II R, 
BAX, MSH6, E2F4, MSH 3 with microsatellite instability is seen in subset of individuals with 
intestinal type carcinoma. Mutational amplification of HER2 gene, TP53 mutation results in 
overexpression of hTERT. About 60% of intestinal type carcinomas exhibit hypermethylation in 
RUNX5. 
Chromosomal Instability 
Nearly 72% of differentiated tumours and 43% of undifferentiated tumours showed 
aneuploidy. The other genetic aberrations are rearrangements in chromosome3, deletions distal 
to 6q21, trisomy8, monosomy 13, aberrations involving 11q13-p15 and translocations. 
CGH studies demonstrated decrease in number of DNA copies in chromosomal arms 
4q,5q,9p,17p, 18q. Increase in DNA copy number in chromosomes 8q,17qand 20q. The loss of 
genetic locus of 3p,4p,4q,5p,8q,13p,17p,and 18q has been demonstrated by Comprehensive Loss 
Of Heterozygosity (LOH) analysis. 
Microsatellite instability 
14-44% of sporadic gastric carcinomas are associated with microsatellite instability. 
MSI-H have loss of expression of MLH/MSH2. The silencing of hypermethylation is said to play 
a pivotal role. It is demonstrated by incresed methylation in the promoter region of MLH1 or 
MSH-I. The unique features of these tumours are all are distally located.They are predominantly 
of intestinal type and is of good prognosis. 
The defective mismatch repair in MSI-H tumours targeted many important proteins 
namely TGFβ  type II receptor (TGFβR2), ACVR2. Other genes affected are IGFRII, hMSH3, 
hMSH6 and E2F-4 involved in regulating progression of cell cycle and signalling apoptosis. 
 
 
 
 
AQUIRED SOMATIC GENETIC/ MOLECULAR ALTERATIONS 
TFF-1 Loss :  
50% of gastric carcinomas demonstrate mutations in TFF1(pS2). Trefoil peptide is a 
molecule with three loops produced by the mucus secreting cells. This is present in chromosome 
21q22. This is associated with gastrokine (GKN)2. This ia a tumour suppressor gene specifically 
associated with stomach. 
E-Cadherin Alteration :  
E-Cadherin is a transmembrane calcium ion dependent adhesion molecule. It is 
associated with sporadic diffuse gastric cancer. It is involved in homotypic interaction of 
epithelial cells. The invasive properties of gastric carcinoma is associated with loss of E-
Cadherin. Decreased expression of this protein in the gastric mucosa when compared to adjacent 
normal gastric mucosa. Methylation of the promoter region of E-Cadherin was found in many 
cases. 
Kinases /Phosphatases:  
P13Kis a lipid phosphatidoyl inositol kinase. It is involved in cellular proliferation, 
adhesion, survival and mortality. 
Methylation silencing alteration: 
Mutations resulting in methylation of the CpG island in the promotor region of p16. The 
tumour suppressor gene RUNX3 inhibits the epithelial cell growth. 
Apoptosis signalling alterations:  
BAX gene promoting apoptosis is mutated in 33% of gastric carcinomas. It is often 
associated with loss of expression of Bif-1(BAX-interating factor) that disrupts the apoptotic 
pathway. Another promoter that upregulates apoptosis is Bcl 2 homologue BAK. Defective 
expression of cell surface death receptors DR4 and DR5 has been observed. 
P53 mutations by allelic loss has been observed in gastric carcinomas. They involve 
mainly the base transitional mutations involving CpG nucleotides. 
HER2/neu which was found to be overexpressed in many gastric carcinomas. It is said to 
have interactions with CD44. CXCR4 is upregulated via epigenetic silencing of micro rna 139. 
VEGF polymorphisms in gastric carcinomas is associated with poor prognosis. Other genes 
implicated are FHIT, chromatic remodelling gene ARIDIA, members of Wnt signalling pathway, 
APC and β- catenin, Hedgehog Target Genes, Human Patched Gene 1 (PTCH1). 
Proteomics in gastric carcinoma 
With invention of new techniques like Protein Chip Array, 2Dimensional electrophoresis, 
Liquid chromatography, iTRAQ (isobaric Tags for Relative and Absolute Quantitation), ICAT 
(Isotope Coded Affinity Tag) proteomic analysis of various abnormal proteins expressed in 
gastric cancers could be done. These involve proteins that act as check points in mitosis such as 
MAD1L1,EBI,HSP27,CYR61 and CLPP. 
SELDI-TOF-MS is Surface Enhanced Laser Desorption /Ionisation Time Of Flight Mass 
Spectrometry.It is a technique that demonstrated upregulation of proteins like pepsinogen C and 
pepsin. It downregulates α- defensins in gastric carcinoma. Fn14 (Fibroblast growth factor 
inducible factor 14) of the TNF family is over expressed in gastric carcinoma. 
MALDI- Matrix assisted laser desorption/ ionisation mass spectrometry done mainly on 
endoscopic biopsies. It uses a unique protein profile that serves as a molecular signal. It is 
composed of 73 signals. It serves to distinguish gastric carcinoma from normal gastric mucosa. 
Many proteins serve to distinguish normal gastric tissue from carcinoma. They either 
getting upregulated as in case of Notch 4, Akt and β catenin. They are downregulated as in 
Cyclin E, p27, E-Cadherin,HIF-3a, NF-KB. Altered expression of HIF-3a and NF-KB is 
associated with increased invasiveness. 
Biomarkers :26  
Serum markers like CEA and CA 10-9 has got  little specificity and sensitivity.  New 
biomarkers like Urokinase Type Plasminogen Activator (U-PA), VEGF, MET, MYC,tie-1 
protein,tyrosine kinases, CD44r6, PDGF-A,TGF-β and cyclin D were studied. Their increased 
levels are found to be associated with incresed invasiveness. Decresed levels of proteins like Kip 
1, CIP1, PAI-I and tPA are associated with increased invasive properties. 
Chemosensitisation markers:26 
1. Overexpression of p53 in advanced gastric carcinomas predicted lower responsive rates 
to chemotherapy. 
2. Increased expression of thymidine synthase or phosphorylase predicts outcome of  
flurouracil therapy. 
3. Tumours with positive staging for BAX and Bcl2 has got poor prognosis. They show 
resistance to chemotherapy drugs. 
Serum markers:26 
                     Increased serum levels of TIMP-1, hepatocyte growth factor, soluble receptors for 
interleukin 2, interleukin 10, soluble fragments of E Cadherin in gastric carcinoma patients has 
been associated with decreased survival rates.These tumours have greater degree of tumour 
invasion. 
 
PRECURSORS OF GASTRIC CARCINOMAS 7 
 
                      Gastric carcinoma precursors are broadly classified into precancerous conditions 
and precancerous lesions. 
PRECANCEROUS CONDITIONS 
         These are clinical  conditions associated with incresed risk of gastric carcinoma. Patients 
with these conditions do not develop gastric carcinoma. They are  
                  1.Epithelial polyps 
                  2. Intestinal metaplasia 
                  3.Chronic gastric ulcer 
                  4. Gastric remnants 
                  5. Hyperplastic gastropathy. 
PRECANCEROUS LESIONS 
            These are the pathological conditions which eventually evolve into gastric carcinomas.  
H.pylori associated chronic gastritis 
 H.pylori has been declared by the WHO as a class I carcinogen.It is the only bacterium to 
assume this status. It causes chronic infection in more than 50% of the population. Its association 
of  is proven in more than 80% of the cases of gastric carcinoma. Statistics state that only 1-3% 
of individuals with H.pylori infection develop gastric cancer.  Host factors coupled with H.pylori 
infection is necessary for the development of carcinoma. 
 H.pylori infection is often acquired during infancy and persists  for life. It colonizes the 
gastric mucosa eliciting an immunological response in the host.It causes multifocal atrophic 
gastritis. The virulence of this gram negative bacteria vary. The strain containing the Cag A gene 
( Cytotoxin associated gene) codes for an oncoprotein. This is  injected by  type IV secretion 
system into the gastric epithelial cells. Once inside the cell  it becomes phosphorylated in motifs 
containing EPIYA sequence. This  starts a chain of events leading to carcinogenesis. This Cag A 
gene  disrupts the intercellular junction. It causes loss of polarity, increases  proliferation, 
reduces apoptosis and leads to carcinogenesis. 
 The organism has another gene the Vac A (Virulence associated gene) . This causes 
apoptosis by introducing cytoplasmic vacoules and pores in  cell membrane. 
 The process of infection generates reactive oxygen species that incites DNA mutation. It  
causes hypermethylation of DNA in the CpG islands. This results in gene silencing associated 
with tumour suppresion. 
 The bacterial membrane has an adhesion protein Bab A (Blood group antigen binding 
Adherin). This adheres to the lewis antigen present in the epithelial cell membranes. This confers 
greater risk of cancer. 
Autoimmune Gastritis 
 It accounts for less than 5% of chronic gastritis. This condition results from the immune 
mediated destruction of parietal cells. It is restricted to the body and fundus. It causes 
neuroendocrine cell hyperplasia resulting in Type I Neuroendocrine tumours. Destruction of 
parietal cells results in lack of intrinsic factor.This leads to Vitamin B12 deficiency, causing 
perinicious anaemia. These individuals have 3 fold increased risk of developing intestinal 
adenocarcinoma. 
Atrophic Gastritis 
  The loss of normal glandular epithelium occurs in two ways. In one  gland is 
destroyed and replaced with lamina propria fibrosis. In the other, glandular loss results from 
replacement of the normal glands by metaplastic epithelium.  
  In H.pylori gastritis this process occurs in the gastric antrum.It occurs in mucosa 
of fundus and body in autoimmune gastritis. This may progress to advanced atrophic 
pangastritis. 
 
 
 
 
METAPLASIA 
 It is the reversible condition. Here one mature cell type is replaced by another mature 
cell. This occurs inorder to prepare the mucosa to withstand adverse conditions. Various types of 
metaplasia occur in stomach. 
Spasmolytic Polypeptide expressing Metaplasia 
 This metaplastic process resembles deep antral glands but lacks  gastrin producing cells.  
Also called antralised oxyntic mucosa, mucous metaplasia or  pseudopyloric metaplasia.These 
metaplastic cells express TFF 2 (Trefoil factor 2).  
TFF are proteins that aids in protection and repair of gastrointestinal tract. TFF1 and 
TFF2 is expressed in stomach. TFF3 also called  intestinal trefoil factor. Expressed by Goblet 
cells of intestine in normal condition . 
 Recent studies have proven a strong association of SPEM in 90% of gastric cancer.It is 
believed to be the first change that preceeds intestinal metaplasia. Role of SPEM as  precursor of 
carcinoma or an associated entity in the carcinogenic process is yet to be proven. 
 
Intestinal Metaplasia 
  It is of three types 
Type I 
It is also called complete or small intestinal type. Consist of absorptive cells, Paneth cells 
and Goblet cells secreting sialomucin. There is increased expression of intestinal mucin MUC 2. 
There is decreased expression of gastric mucin MUC 1, MUC5AC and MUC 6. It  is the most 
predominant subtype and seen  mostly in  benign conditions. 
Type II 
It is also called incomplete, immature or the colonic type. Charcterised by lack of 
absorptive cells. There is presence of varying stages of differentiation of columnar or 
intermediate cells. They secrete neutral and acid sialomucin and goblet cells. The predominant 
mucin type is Sialomucin. 
Type III 
The predominant cell type is Sulphomucin secreting intermediate cells.Percentage of 
association of  type III intestinal metaplasia with gastric carcinoma  is often less than 10%. 
 
Gastric  polyps 26 
                   The epithelial polyps of the stomach are of many types. They are hyperplastic, 
inflammatory, heterotopic and hamartamatous polyps. Majority of the gastric polyps are fundic 
gland polyps. They can occur sporadically or as part of familial adenomatous polyposis 
syndrome. A recently diagnosed entity is an Autosomal dominant condition termed Gastric 
adenocarcinoma and proximal polyposis syndrome.It is characterised by development of 
numerous fundic gland polyps. There is associated  dysplastic changes in the gastric epithelium. 
 Hyperplastic polyps are found in the setting of  H.pylori infection.They are associated 
with dysplasia in 1-3%. 
 1-4 % of the gastric polyps are adenomas. They are classified based on architechture as 
tubular, villous or tubulovillous. Based on epithelial phenotype they are  subclassified into 
gastric and intestinal type adenoma. 
 
Intestinal type adenoma 
They are common in males, often occuring in antrum.  Composed of cells with elongated 
hyperchromatic nuclei, goblet cells and paneth cells. Associated with chronic gatritis and 
intestinal metaplasia.They have a  high risk  for malignant transformation.  
Gastric adenomas 
Foveolar type 
Occurs in association with Familial Adenomatous Polyposis. Present predominantly in 
body. Composed of cells with oval to round nucleus, pale cytoplasm. They contain apical mucin. 
Pyloric type 
More common in females. Associated with autoimmune gastritis and intestinal 
metaplasia. Has a high risk for malignant transformation. Composed of cells with round atypical 
nuclei with ground glass cytoplasm. 
Oxyntic type adenoma 
Negligible risk for malignant transformation. Composed of chief cells and mucous neck 
cells. 
 
 
Chronic gastric ulcer 7 
                     Cancer involving the margin but not the base of a chronic ulcer. Ulcer-cancer was a 
term coined by Hauser in 1926.. This term is not commonly used nowadays. A chronically 
ulcerated epithelium is more susceptible to carcinogenic stimulus. This is postulated to be the 
reason for this phenomenon. 
Gastric remnants 7 
 The increased incidence of carcinoma has been reported in a subset of  individuals. These 
group of individuals underwent Billroth II gastrectomy for duodenal ulcer.The incidence was 
influenced by the  operation – carcinoma interval.  Usually develops nearly 10 years following 
the surgical procedure. The stoma is the most common site.  Both type of carcinomas -intestinal 
and diffuse has been reported. The probable mechanism of carcinogenesis is the loss of 
sphincteric action. The gastro enterostomy stomal site is thus subjected to a constant bile 
exposure. This causes  mucosal abnormalities eventually turning to gastric carcinoma.  
Hyperplastic gastropathy 7  
 The thickening of the gastric mucosa in seen in two conditions  
Zollinger Ellison syndrome 
There is glandular hyperplasia with hyperacidity . No risk of malignancy. 
Menetriers disease 
There is mucus cell hyperplasia with protein loss. Probable risk of malignancy. 
Chronic hypertrophic glandular gastritis of schindler 
Increase in the normal looking glandular elements. 
PRECANCEROUS LESIONS OF STOMACH 7 
  These conditions which precedes the development of carcinoma. Eg.,Dysplasia. 
Dysplasia 
  Abnormal state of tissue charecterised by pronounced cellular and structural 
alterations. They have increased  propensity for malignant transformation. 
Various studies have classified dysplasia they are, 
1) Cuello classification  
Hyperplastic type 
Adenomatous type 
2) Jass classsification 
Type I or Adenomatous lesion 
Type II or Non adenomatous lesion 
 
3) Vienna classification 90 
Category 1 – Negative for neoplasia / dysplasia 
Category 2 – Indefinite for neoplasia / dysplasia 
Category 3 – Non invasive low grade neoplasia 
Category 4 – Non invasive high grade neoplasia  
Category 5 – Invasive neoplasia 
   Intramucosal carcinoma 
   Submucosal carcinoma 
4) WHO Classification 
Low grade dysplasia 
High grade dysplasia 
Low grade dysplasia 
 Confined to superficial part of mucosa. 
 Composed of simple dysplastic tubules with little branching 
 .They lie underneath the  normal foveolar epithelium. 
 The cells have a basal nucleus with a small indistinct nucleoli 
 Sparse mitosis 
High grade dysplasia 
 Architectural changes like elongation, budding often producing cribriform pattern. 
 The cells have an enlarged Vesicular nucleus with irregularly clumped chromatin and 
irregular nucleoli. The nuclear cytoplasmic ratio is increased with loss of nuclear polarity. 
 
Intramucosal Adenocarcinoma 
  The neoplastic cells invade into the lamina propria  or the muscularis mucosa. They 
don’t invade the submucosa. 
Criteria for invasion 
 Presence of single cells or clusters, budding of tumour cells into the lamina propria. 
There should be architectural distortion with fusion of glands. This condition should be 
differentiated from high grade dysplasia. 
 The Correa cascade26 is a chain of events believed to occur following a H.pylori 
infection. Over a period of years it culminates in  adenocarcinoma. 
 
 
Normal gastric mucosa 
Chronic H.pylori Gastritis 
 Genomic instability, DNA methylated 
Atrophic Gastritis 
 
Intestinal Metaplasia 
Mutations APC, TP53 
Dysplasia 
Mutations TP53, K-RAS,LOH-TP53  APC, DCC 
Intestinal type Carcinoma 
 CLASSIFICATION OF GASTRIC ADENOCARCINOMA 
 
Early gastric cancer7 
 It is the primary carcinoma confined to the mucosa and submucosa regardless of nodal 
metastasis. The term early implies the feasibility of complete surgical resection. It is  not related 
to the time period of evolution. 86 % of the lesions are larger than 2 cm. Endoscopic screening 
helped identifying small cancers (<10 mm in size) and minute cancers (<5 mm) in size. 
 
Macroscopic classification 
 
Type I – Protruding type – An irregular nodular lesion with clefts between papillary projection. 
Type II 
   IIa – Superficial elevated type – Mucosal elevation twice its normal size to 5mm. 
IIb – Superficial flat type –Lesion is at the same level with surrounding mucosa. 
IIc –Superficial depressed Lesion presents as a shallow depression. It is the most 
common type.It is further classified by Nagayo et al into 
  IIC - <3cm, well demarcated lesion. 
  IIC ’ - >3cm, poorly demarcated, also called superficial spreading type. 
Type III – Elevated ulcer with a strip of carcinomatous epithelium forming the border. 
Extremely rare. 
  
Majority of the early gastric cancers are of tubular or signet ring type. Presence of an 
ulcer in a lesion of <3 cm aids in its conversion into a submucosal malignancy. In contrast to 
lesions > 3cm where submucosal invasion occurred in the absence of ulceration. The presence of 
ulceration accelerates nodal metastasis. 
 
Lymph node invasion 
 The extent of nodal metastasis depends on the size of primary tumour. For tumour  <1cm 
diameter the risk is 4% and for tumour >4cm the risk increases to 18%.  Metastasis was confined 
to primary regional nodes in lesions confined to mucosa. Lesions with extension into the 
submucosa  involves the secondary and tertiary nodes. 
CLASSIFICATION SYSTEMS USED IN GASTRIC CANCER 7,25,26 
 
I. Borrman’s system 
It is based on gross appearance of the tumour. 
 
 Superficial carcinoma – Type 0 / early carcinoma 
 Polypoidal – Type 1 / Nodular broad based growth without ulcer 
 Fungating – Type 2 / Nodular lesion with an ulcer whose base lies above 
the stomach level. 
 Ulcerated – Type 3 / Excavated lesion penetrating  stomach wall. They 
have tumour cells in their base and margin. 
 Diffusely infiltrative – Type 4 / Linitis plastica – Thickening of the 
stomach wall without obvious growth or ulceration. Also called scirrhous 
carcinoma 
 
 
II. Lauren’s classification  
It is based on microscopic appearance 
 Intestinal type – Resembles a colonic carcinoma. Common in older male 
patients and have a high rate of survival. 
 Diffuse type – Tumour cell infiltrates as individual cells in a diffuse 
manner. Common in young females. 
 Intermediate type 
III. Mings classification 
 Expanding – Grows as a well defined nodule or mass. It compress the 
near by tissues.Associated with high lymphocytic infiltration. 
 Infiltrative – Grows as diffuse infiltration of individual tumour cells. 
Associated with intense desmoplasia. 
IV. Nakamura classsification – on the basis of gland formation. 
 Differentiated 
 Undifferentiated 
V. Mulligan classification89  
 Intestinal type 
 Mucous cell 
 Pyloro cardiac 
VI. Goseki’s classsification 25 
  I- well differentiated tubules, intracellular mucin poor 
  II - well differentiated tubules, intracellular mucin rich 
III- Poorly differentiated tubules, intracellular mucin poor 
  IV- Poorly differentiated tubules, intracellular mucin rich 
VII. Carneiro classification – histological classification 
 Glandular 
 Solid – has good prognosis 
 Isolated 
 Mixed 
VIII. Adachi classification 
  Better prognosis  - Tubular 
Solid 
Mucinous tumours with well differentiation 
  Poor prognosis - Signet ring type  
Scirrhous  
Mucinous tumours with poor differentiation 
IX. WHO CLASSIFICATION OF GASTRIC CARCINOMA4 
EPITHELIAL TUMOURS 
PREMALIGNANT LESIONS 
 Intraepithelial neoplasia (dysplasia),low grade 
 Intraepithelial neoplasia (dysplasia),high grade 
CARCINOMA 
 Adenocarcinoma 
 Papillary adenocarcinoma 
 Tubular adenocarcinoma 
 Mucinous adenocarcinoma 
 Pooly cohesive carcinoma(including signet ring cell 
carcinoma and  other variants) 
 Mixed carcinomas 
 Adenosquamous carcinoma 
 Carcinoma with lymphoid stroma(Medullary carcinoma) 
 Hepatoid carcinoma 
 Squamous cell carcinoma 
 Undifferentiated carcinoma 
NEUROENDOCRINE NEOPLASMS 
 Neuroendocrine tumours (NET) 
 NET G1 (Carcinoid) 
 NET G2 
 Neuroendocrine carcinoma (NEC) 
 Large cell NEC 
 Small cell NEC 
 Mixed adenoneuroendocrine carcinoma 
 EC cell, serotonin producing NET 
 Gastrin producing NET (gastrinoma) 
MESENCHYMAL TUMOURS 
 Glomus tumours 
 Granular cell tumour 
 Leiomyoma 
 Plexiform fibromyxoma 
 Gastrointestinal stromal tumour 
 Kaposi sarcoma 
 Leiomyosarcoma 
 Synovial sarcoma 
Lymphomas 
Secondary tumours 
Diffuse type of gastric adenocarcinoma26 
Popularly known as the linitis plastica. This carcinoma presents with diffuse thickening 
of the stomach wall. Mostly sporadic but 10% of the cases are inherited. 
Hereditary diffuse gastric carcinoma : 
   It is due to dysregulation of three epithelial junctional proteins.They are involved in 
cellular interaction and adhesion.They is responsible for the development of hereditary diffuse 
type of gastric carcinoma. The three molecules are : 
1. E. cadherin – A calcium dependent adhesion molecule. 
2. Claudin – Tight junction proteins. 
3. Connexions – Gap junction proteins. 
         Hereditary diffuse gastric cancer is inherited as an autosomal dominant condition. It 
occurs due to germline mutation in CDH1.Second hit mutation is necessary in these 
mutant carriers to initiate carcinogenesis.   
Carneiro model of hereditary diffuse gastric cancer  
Normal gastric mucosa 
 
LDH – CDH 1                            
                                             
Signet ring cell carcinoma insitu 
 
     
Invasive Signet Ring Carcinoma 
  Signet ring cell carcinoma in situ 
 
             Characterised by pagetoid spread of  signet ring cells beneath  foveolar epithelium. 
 
 Glands & foveola have an intact basement membrane  lined by signet ring cells. These cells   
have an eccentrically placed nucleus and mucous vacoules. These tumours are characterised by 
presence of low E- cadherin levels. Hence  E –cadherin mutation is probably the earliest event in  
genesis of diffuse gastric Cancer. 
 
Sporadic diffuse gastric cancer  
 
               Associated with H. pylori infection which induces methylation of the promoter region.  
 
There is associated silencing of E-cadherin. Methylation is reversible after H. pylori eradication. 
 
 Diffuse gastric cancer is  considered the most aggressive neoplasms. An exception to this is the 
desmoplastic  variant that carries good prognosis 
Tubular adenocarcinoma 4,7 
     Composed of tubules of varying sizes.They showing branching, dilatation or slit like   
compression.Cells are cuboidal, columnar or may be flat due to intraluminal mucin. 
Well differentiated 
Glands of various sizes with minimal branching. The cells are either columnar or 
cuboidal. They have a pleomorphic basal nuclei, with thick nuclear margin and coarse chromatin. 
Moderately differentiated  
The glands are complex, irregular with marked architectural atypia. The tumour cells 
have a round  irregular nuclei with loss of polarity and coarse chromatin. 
Poorly differentiated  
The cells are arranged in solid sheets and cords.There is sparse glandular elements. The 
nucleus is highly pleomorphic with numerous mitotic figures. 
Papillary adenocarcinoma 
 These are well differentiated tumours composed of arborizing papillary projections. 
These projections have a core of fibrovascular connective tissue. These cores are lined by 
cuboidal cells that maintain polarity. The tumour shows clear demarcation with inflammatory 
cell infiltration. 
Mucinous adenocarcinoma 
  Volume of mucin should be more than or equal to 50% of tumour volume. The tumour 
presents as small clumps of cells floating in pool of mucin. It can also present as glandular 
structures lined by mucin secreting cells. 
Signet ring cell carcinoma 
  Tumour is composed of dispersed or small clusters of malignant cells. The cells can 
resemble a signet ring with nucleus pushed to one side due to intracytoplasmic mucin. They stain 
with alcian blue at pH 2.5 due to acidic mucin.  
The Cells can also have varying morphology. Such as cells with centrally placed nucleus 
mimicking histiocytes, Neutral mucin containing small eosinophilic cells, Cells with scant 
mucin. The cells elicit a dense desmoplastic response. 
 
Variants 6,35 
1)Adenosquamous  
Rare tumour constituting <1%. Also called adenoacanthoma. The extent of squamous 
differentiation is variable. A number of hypothesis have been put forth regarding its 
pathogenesis. Most popular is the totipotent stem cells going for bidirectional differentiation. It is 
also believed to arise from metaplastic squamous epithelium. 
Gross  – Ulcerating large tumour 
 
Microscopy 
The squamous and the glandular element are intermingled. The squamous component 
should  form  >25% of tumour volume. The glandular element is predominantly of intestinal type 
with areas of metaplasia. The squamous component show varying degrees of differentiation. 
 
Gastric carcinoma with a Lymphoid stroma 9,35 
 First described in the Japanese population. Mimicks medullary carcinoma of breast. 
Affects cardia or the gastric stump. Common in men. Associated with EBV infection in 80% of 
cases. 
Microscopy 
Cellular lesion.Composed of sheets of cells with abundant cytoplasm, uniform nuclei 
with prominent nucleoli and coarse chromatin. The cells are PAS positive. Admixed with 
abundant lymphocytes that are predominantly CD8+ve T cells, plasma cells and giant cells. The 
giant cells are believed to formed due to interferon γ released by T cells. 
 Insitu hybridisation studies have demonstrated non polyadenylated RNA-1 (EBER). This 
is coded by EBV expressed in the nucleus of giant carcinoma cell. 
 
Gastric carcinoma with extensive Neutrophilic infiltration35 
 Occurs commonly in women, associated with better outcome. Reported in anaplastic 
carcinoma with pleomorphic cells admixed with neuterophilic infiltration. It is due to the IL-8 
produced by tumour cells. 
 
 
 
Carcinoma with Rhabdoid feature35 
Gross  
 Exophytic masses or ulcers. 
Microscopy  
Solid or poorly cohesive cells in diffuse pattern with minimal stroma. The individual cells 
have an eccentrically placed vesicular nuclei, abundant eosinophic cytoplasm with large 
inclusion. 
IHC 
Vimentin and cytokeratin positive. It is an aggressive carcinoma with bad prognosis. 
 
Hepatoid and Alpha feto protein producing adenocarcinoma5,39 
 These tumours resemble hepatocellular carcinoma. Composed of polygonal cells with 
abundant granular eosinophilic cytoplasm. They are admixed with adenocarcinomatous 
components in either tubular or papillary pattern. 
 It is believed to develop due to the embryonal endodermal development towards liver and 
stomach. 
 Tendency  to go for venous invasion and liver metastasis. Has a poor prognosis. 
Special stains  
The HCC component shows PAS positivity with diastase resistance in 50% of the 
tumour. 
IHC 
Positive for α feto protein, CEA, Albumin, α1 antichymotrypsin. 
 
 
TERATOMA 7 
 Extremely rare, few cases have been reported in literature. Presents in infants with 
features of abdominal mass, obstructive symptoms and bleeding manifestation. 
Gross 
The tumour projects into the gastric lumen or into abdominal cavity. 
Microscopy 
Composed of elements from all  three germ layers. Treatment is by surgical resection. 
 
CHORIOCARCINOMA 7,35 
                       Cells positive for HCG are in the neck region of normal gastric glands. These are 
predominantly α subunits. 
Clinical features  
Can affect  both sexes. An affected male often presents with Gynaecomastia .  
Microscopy 
Tumour is composed of malignant cytotropohoblast and syncitiotropoblasts. They are admixed 
with adenocarcinomatous component with varying differentiation. 
Often admixed with embryonal carcinoma and yolk sac tumour. Patient has elevated 
serum β HCG levels. Placental lactogen and pregnancy specific glycoprotein may also be 
elevated. 
IHC 
 Immuno reactive for α and β HCG. 
 
 
 
CARCINOSARCOMA 7,35 
 It is seen in young individuals, usually at pylorus. It carries a poor prognosis 
Microscopy 
 Present as collision tumour with carcinomatous and sarcomatous elements meeting at 
interface. It also presents as composite tumour showing irregular admixture of both elements. 
The carcinomatous element is predominantly adenocarcinoma .The sarcomatous element shows 
differentiation towards rhabdomyosarcoma, leiomyosarcoma or chondrosarcoma. 
IHC 
The epithelial elements are positive for CEA, EMA and cytokeratin. The sarcomatous 
elements are positive for vimentin and desmin. 
 
GASTRIC NEUROENDOCRINE NEOPLASMS26 
 The incidence of gastric carcinoid which was considered to be rare in the past is 
increasing. This is attributed to the increased endoscopic screening. These tumours are 
categorized based on their etiology as gastrin dependant (type I & II) and gastrin independent 
neoplasms (type III) 
Type I gastric carcinoid 
  Occurs in the setting of  atrophic gastritis and intrinsic factor deficiency. Associated  
with long term usage of proton pump inhibitors. Common  in women in 5th - 6th decade. 
Gross  
Small lesions measure <1cm. Occur as multi centric   polypoidal projections often located 
in the fundus. Confined to mucosa and submucosa. There is no vascular invasion.  
Larger lesions measures > 1cm, either single or multiple. It is a low grade malignant 
neoplasm. Larger lesions have propensity for nodal and vascular involvement. 
Microscopy 
Entire spectrum starting from endocrine hyperplasia, adenomatoid hyperplasia, endocrine 
cell dysplasia and neoplasia may be present. They are well differentiated, benign grade I lesions 
with Ki-67 status <1%. 
Molecular pathology 
Loss of heterozygosity in 11q13-14 indicating  involvement of MEN-1 gene. There is 
loss of methylation of LINE(1) [ Long interspersed nucleotide element type 1] 
 
Type II gastric carcinoids  
 It is associated with Zollinger Ellison syndrome, Diabetes, Hypothyroidism, MEN-1 
syndrome and other endocrine abnormalities. These intermediate grade neoplasms present as 
multiple lesions of size <1cm. 
 Microscopy 
 They mimic type I lesion except for an increased tendency for local invasion and 
metastasis. They are well differentiated lesions with low or negligible malignant potential. 
Molecular pathology 
 Loss of  heterozygosity and germline  mutation that disrupts Menin function.  
Inactivates cell cycle inhibitors like P16INK4A50  that results in  loss of stimulus to inhibit 
cell proliferation. 
 
 
 
 
 
Type III gastric carcinoids  
 These particular subsets of carcinoids are sporadic.  Associated with normo-gastrinemic 
state.  Occurs in men in 5th - 6th decade. They can be functioning resulting in atypical carcinoid 
syndrome or non functioning mimicking an adenocarcinoma. 
Microscopy 
Composed of round cells  with uniform centrally placed nuclei. Has characteristic salt 
and pepper chromatin, inconspicuous nucleoli with occasional mitosis. The cells may assume a 
variety of architectural patterns. They form cords, ribbons with occasional rosette formation. 
These tumours are graded according to the mitotic activity and Ki-67 immuno-labelling 
 
Grade Mitotic activity Ki-67 immunolabelling 
G1 < 2mitosis / 10 HPf <2 % 
G2 2-20 mitosis / 10 HPf 3-20 % 
G3 >20 mitosis / 10 HPf >20 % 
 
Type III carcinoids comprise small cell and large cell neuro endocrine carcinoma. 
IHC 
Positive for Chromogranin A, Synaptophysin, Serotonin, Pancreatic polypeptide, 
Histamine, Gastrin, Corticotropin, β-Melanocytic stimulatory hormone and Epinephrine. 
Electron microscopy 
Presence of dense core neuro secretory granules 
 
Oncocytic Carcinoma6 
 The tumour is composed of solid sheets of cells. The cells have abundant granular 
eosinophilic cytoplasm. 
Special stains: PTAH and Luxol fast blue 
Electron microscopy: Numerous mitochondria, tubules, vesicles, intracellular canalicular 
system and microvilli filling the intercellular lumen. 
 
Fundic Gland Adenocarcinoma 6 
 It has predominantly chief cells. The cells have grayish blue cytoplasm and atypical 
nuclei. Commonly occur in proximal stomach and has good prognosis. 
 
Gastric carcinoma with Osteoclast like giant cells6 
 The tumour cells are admixed with numerous multi nucleated giant cells. 
 
Acinar cell carcinoma6 
 It is believed to arise from the region of pancreatic metaplasia. 
 
 
Other rare variants6 
 Clear cell carcinoma 
 Micropapillary carcinoma. 
 
 
 
GASTROINTESTINAL STROMAL TUMOUR26  
 These are spindle cell neoplasms that are CD117 positive. It is the first tumour to be used 
in the targeted therapy of group of drugs called Tyrosine kinase inhibitors. 
Cell of origin: The gastric pace maker cells or the Interstitial cells of Cajal. They are present 
admixed with the myentric plexus of stomach. 
Clinical features 
 Asymptomatic, may present with pain, bleeding manifestations and anemia. Common in 
people in the age group of 50-60 years. No known risk factors. 
Gross 
They can present as a dome shaped submucosal nodule or as a dumb bell shaped lesion 
with a narrowed segment in the muscularis propria and bulbous portion on both submucosa and 
serosa. Cut surface is firm to rubbery in consistency. Cut surface is grey white to yellow with 
areas of secondary degeneration. 
Microscopy 
The tumour assumes two pattern, the spindle cell type and epitheloid cell type. The 
spindle cell  have a blunt elongated nucleus with a perinuclear cytoplasmic vacuole. They can 
assume varying pattern in forms of interlacing or interdigitating fascicles. 
 The epitheloid cell type is composed of sheets of cells with abundant cytoplasm, centrally 
placed round nucleus, prominent nucleoli & a perinuclear halo. 
Prognostic feature 
 Include the tumour size and mitotic activity. Tumour <2cm and not more than 5 
mitosis/50 HPf   have a good prognosis. 
 
 
Predictors of metastasis 
Growth pattern, cellularity, type of cell, degree of proliferation and necrosis. 
IHC 
>95 % of the tumours are positive for KIT. The positivity can be membranous, 
cytoplasmic or a perinuclear dot. 
 Tumours that are KIT negative are positive for Anoctamin-1(Ano-1). It is a chloride 
channel protein in the cajal cells.Ano-1 is also called DOG-1 (Discovered on GIST) or  
ORAOV2 (Overexpressed in oral carcinoma) 
Molecular genetics 
 Mutation in KIT or PDGFRA  leads to  activation due to self phosphorylation 
independent of ligand  binding. 
 
GASTRIC LYMPHOMA5,21,23,26 
Lymphoid neoplasms of the stomach are classified into Hodgkins and Non-hodgkins 
lymphoma. The GIT  is  the most frequent site of occurrence of extranodal NHL. 
 The most common tumour in this category is Marginal Zone B Cell Lymphoma. The 
other tumours are Mantle cell lymphoma, Burkitt lymphoma, DLBCL, T cell lymphoma and 
Hodgkin’s lymphoma. 
Pathogenesis 
The initiating stimulus in most cases is chronic H.pylori associated gastritis. It results in  
development of an organized lymphoid follicle in the gastric mucosa. These lymphoid follicles 
resemble the mucosa associated lymphoid tissue.It shows infiltration of the surface epithelium 
mimicking the intestinal Payer’s patches. Infection with H.pylori causes neoplastic proliferation 
of cells in the mucosa associated lymphoid tissue. 
Gross 
Low grade lymphomas present as vague submucosal nodules. High grade lymphomas 
presents as   exophytic  mass associated with ulceration. 
Microscopy 
Composed of heterogenous population of  centerocyte  like cells, plasma cells and large 
lymphocytes. They are admixed with reactive lymphoid follicles. They are characterised by  
lymphoepithelial lesions. They are small groups of atypical lymphocytes invading the glands and 
causing destruction of the glandular epithelium. This feature may not always be present. 
Sometimes only few scattered epithelial cells  are admixed with sheets of lymphoid cells. There 
is expansion of lamina propria by the lymphoid cells. It is necessary to examine the muscularis 
mucosa. It is not infiltrated by the usual lymphoid collections but do so in the presence of MALT 
lymphoma. 
Diagnosis 
The biopsies obtained by gastric mapping ensure adequate sampling of the gastric 
mucosa. Endoscopic ultrasound is recommended to predict the depth of invasion. The tumour is 
staged using Ann Arbor classification. The other alternative systems used are Paris staging 
system. 
IHC 
The neoplastic cells express pan B cell markers like CD20 and are negative for CD5, 
CD10, CD11c. 
 
Molecular genetics 
 t(11;18)(q21;q21), t(1;14)(p22;q32), t(14;18)(q32;q21), t(3;14)(p14.1;q32) they result in 
activation of NF-kB. 
MESENCHYMAL TUMOURS5 
Schwannoma 
 These are well circumscribed benign lesions. Occur in the middle aged individuals. 
Microscopically the tumour is composed of palisading spindle cells cuffed by lymphocytes. 
IHC: Positive for S-100 and GFAP, negative for CD117, CD34, desmin, actin. 
Leiomyoma / Leiomyosarcoma 
 These are rare circumscribed solitary neoplasms usually located in the cardia. Tumour is 
composed of spindle cells with a blunt edged nucleus and eosinophilic cytoplasm arranged in 
whorls and fascicles. 
IHC 
Positive  for Actin and desmin. 
Electron microscopy 
Prominent basal lamina with plaque like sub plasmalemmal  structures, bundles of 
microfilament and cell membrane based pinocytic vesicle. 
Glomus tumours 
 The common site is antrum. Arise from pericapillary cells of glomus bodies. These 
tumours are composed of sheets of round cells with uniform nuclei and pale eosinophilic 
cytoplasm. May be admixed with hyalinized or myxoid areas. 
Special stains 
Pericellular stain pattern with reticulin. 
Vascular tumours 
 Hemangiomas, Lymphangiomas, Hemangioendotheliomas, Kaposi sarcoma and 
Angiosarcomas are the vascular neoplasms occurring in stomach.  
Gastroblastoma 35 
 This rare biphasic tumour is composed of dual population of mesenchymal and epithelial 
cells. The sheets of bland spindle cells are admixed with small aggregates of epithelial cells. 
Both elements are bland. 
 
Other rare tumours of stomach21 
1) Synovial sarcoma 
2) Plexiform fibromyxoma 
3) Granular cell tumour. 
 
Metastatic tumours  to stomach 
 The common tumours to metastasize to stomach are lobular carcinoma breast, renal cell 
carcinoma, Melanoma, Hepatobiliary carcinomas. Distinctions from primary gastric tumours are 
mainly by usage of IHC.  
 
SPREAD OF GASTRIC CARCINOMA:6 
                   Carcinomas of the proximal stomach have a propensity to involve the lower 
oesophagus. Carcinomas of the distal  stomach  tend to involve the duodenum. 
            Tumours having an infiltrative pattern of growth are more prone to serosal involvement. 
They produce an advanced tumour stage. They can also involve adjacent organs such as spleen, 
pancreas,colon and omentum. Spread to the loco regional nodes occur via the mucosal and 
submucosal lymphatic plexus of stomach. Tumours produce deposits in perigastric, para aortic 
and coeliac nodes. Tumours of the distal third of the stomach involve the hepatoduodenal nodes. 
Infrequent sites of metastasis are lungs, ovaries and adrenal glands. Gastric adenocarcinomas 
also produce vascular invasion. 
                Krukenberg’s tumour is the bilateral ovarian metastasis arising from diffuse gastric 
carcinoma. Intestinal type of gastric adenocarcinoma with ovarian metastasis  simulate surface 
epithelial neoplasms. Cutaneous metastasis from gastric adenocarcinoma can resemble a primary 
adenexal tumour. Metastasis to the liver is more common in intestinal type of gastric 
adenocarcinoma. It spreads in a intra sinusoidal pattern. This results in hepatic failure. Diffuse 
type of gastric carcinoma   involves the lungs and ovary. 
 
TREATMENT OF GASTRIC CARCINOMA6 
        Surgical resection is the treatment of choice in gastric adenocarcinoma. The decision for 
gastrectomy is made largely on the basis of the extent of invasion of the gastric wall by the 
tumour proper. Gastrectomy is accompanied by lymph node dissection and splenectomy in some 
cases. 
 Total gastrectomy : Tumours involving the gastric cardia or higher up in the lesser or greater 
curvature. Carries  the disadvantage of higher morbidity. 
Sub total gastrectomy: Tumours of distal half of the stomach. The main disadvantage is that it 
carries a probability for recurrence in the remnant gastric stump. 
     Gastric carcinoma shows very little response to radiotherapy and chemotherapy. 
 
PROGNOSTIC FACTORS IN GASTRIC CARCINOMA6 
1. Age of the patient 
Gastric carcinoma occurring in younger individuals carries bad prognosis. This is 
attributed mainly to the late diagnosis. Also, there is increased incidence of diffuse type 
of gastric adenocarcinoma . 
2. Tumour stage 
The depth of penetration of the tumour into the serosa serves as an important 
factor in predicting the extent of metastasis. In individuals with serosal  involvement, the 
surface area of the tumour involvement is also important in deciding the prognosis. 
3. Anatomical location 
Long term survival is higher in individuals who have tumours involving the distal 
half of the stomach. Survival rates are lowered in tumours of oesophagogastric 
junction,fundus and cardia. 
4. Margins of tumours 
Tumors with pushing borders carry a good prognosis when compared to those 
cases involving the stomach wall in a diffuse manner. 
5. Size of the tumour 
 Tumours with small size carry a better prognosis when compared to larger 
tumours. 
6. Histological type and grading 
Lauren’s intestinal type is said to be associated with better prognosis when 
compared to diffuse type of tumours. The Goseki classification system takes into account 
the extent of gland formation and content of intracellular mucin. It is said to be a better 
predictor of survival. Among the diffuse type of carcinomas better prognosis is attributed 
to the desmoplastic low grade tumours. Anaplastic high grade tumours having worse 
prognosis. Tumours in increasing order of malignancy are cohesive tumours of intestinal 
and solid type, diffuse tumours, mixed tumours, small cell  neuroendocrine carcinoma 
and adenosquamous carcinoma. 
7. Inflammatory reaction  
Advanced stage tumours have abundant S 100 protein positive langerhans cells. 
Presence of inflammatory cell infiltrates in tumour interface and degenerative changes in 
tumours is associated with good prognosis. 
8. Peri neural invasion  
Tumours with perineural invasion are associated with bad prognosis. 
9. Resected margins  
Positive resected margins predict early tumour recurrence. 
10. Regional lymph node involvement 
Tumours with negative nodal involvement is said to have 50% 5 year survival rate. 5 
year survival rate is <10% in tumours with lymph node metastasis. The number of nodes 
involved carries much prognostic significance than the staging.  Micro metastasis in 
lymph nodes demonstrated by immunohistochemistry carries a prognostic significance. 
11. Surgery performed  
Survival rates are higher with Radical subtotal gastrectomy (22.1%). Radical 
lymphadenectomy is said to carry a good prognosis when compared to standard 
lymphadenectomy. 
12. Molecular biology: 
 The rate of cell proliferation determined using markers like P105, PC10 and DNA ploidy 
analysis using flow cytometry serves as an indicator of prognosis. 
 Over expression of HER 2Neu is said to be one of the independent prognostic factor in   
gastric carcinoma.  
 Increased expression of P53 is associated with decreased survival 
 Increased levels of cathepsin is associated with poor survival and propensity for invasion 
and metastasis. Increased expression of p27kip1 is associated with poor survival. 
 Loss of FHIT protein is associated with poor prognosis. 
 Increased expression of the T Antigen ,a precursor protein of blood MN system is 
associated with invasion and metastasis. 
 
HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR/ HER2Neu11,13,21,28,29,30 
 
 HER2Neu also known as ErbB 2 is a 185 kilo dalton receptor. It is becoming popular in 
the past few years. It is considered a molecular target for targeted therapies in various 
carcinomas27. Knowledge on the molecular structure and functioning of this receptor is 
important. It helps us to understand its mode of action and therapeutic significance. 
ErbB belongs to a family of tyrosine kinase receptors, that include four members 
ErbB1/HER1, ErbB2/HER2, ErbB3/HER3, ErbB4/HER4. They exert their influence in a number 
of steps of oncogenesis. They influence proliferation of cells, their survival, angiogenesis, cell 
migration  invasion.28,29 
The role of HER2 in tumorigenesis is due to its amplification. This abnormally 
overexpressed protein is associated with carcinomas of breast, stomach, oesophagus, colon, 
endometrium, cervix, ovary, lungs and the urothelium. The ErbB protooncogene on Ch17q21 
codes for a transmembrane tyrosine kinase receptor. 
 This receptor has a functional intracellular domain of tyrosine kinase. It has a lipophilic 
membrane spanning domain with  an extracellular ligand binding region.29 The ligands for these 
receptors are members of EGF related peptide growth factor family.  
They are produced as transmembrane precursors. They undergo proteolysis to produce 
soluble growth factors. These ligands are grouped into three categories. 
The first group comprise receptors specifically binding to Erb B1- amphiregulin (AR), 
Transforming growth factor alpha (TGF-α). The second group of receptors show dual specificity 
to both ErbB1 and ErbB4, include betacellulin (BTC), heparin binding EGF (HB EGF) and 
epiregullin (EPR).  
The third group of receptors are the neuregulins. They are further sub divided   based on 
their binding affinity for both ErbB3 and ErbB4 (NRG 1 & NRG 2) or ErbB4 only (NRG 3 and 
NRG 4)28. 
Mechanism of Action29 
Binding of  ligand to the receptor results in their dimerisation, activation of cytoplasmic 
domain and phosphorylation. This process provides a docking site for the signaling molecules. 
This in turn results in the activation of RAS MAPK pathway. All this causes cell proliferation 
and inhibition of apoptosis via the PI-3K-AKT  mTOR pathway. 
 
 
Role of HER2/Neu11 
The Neu proto oncogene is the rat homologue of HER2. It was first described when DNA 
from rats with neuroblastoma induced by a process of chemical carcinogenesis with nitrosoethyl 
urea was transfected to fibroblasts. 
All members of EGFR family possess specific ligands except HER2. No particular ligand 
has been associated with HER2/Neu. This property may be attributed to a point mutation 
occurring in the base pair in position 2012 that replaces valine with glutamic acid. This mutation 
is localized to the transmembrane region that paves way for the activation of receptor without 
binding of a ligand. 
Uniquness of HER 2/Neu 27 
Has no specific ligand and undergoes constitutional activation. This molecular behavior 
is responsible for the uncontrolled cell proliferation and increased cell survival in the absence of 
growth factors resulting in malignant transformation. 
Role of HER2/Neu in Gastric Carcinoma 
        Gene amplification of HER2/Neu and its overexpression in gastric and  gastrooesophageal 
carcinomas was first described in 198627. The advent of targeted therapies in inoperable cancers 
had led to the therapeutic implication of HER 2/ Neu positive gastric carcinomas.30 
Literature has reported varying positivity rates for HER2/Neu expression in gastric 
carcinomas. It ranges from 7-43%13. Initially the scoring system was based on the criteria for 
breast tumours but it resulted in a number of false negative results.  
In order to avoid this under reporting a new grading system was devised for gastric 
carcinomas. This could be applied to cases diagnosed on both biopsies and gastrectomy 
specimens. 
The disadvantage of using a biopsy material is that often an inadequate material may be 
obtained. Also exhaustion of tissues in the blocks prevents additional investigations. The biopsy 
obtained is often subjected to crush artifacts. 
It has been recommended that due to tumour heterogenicity and nonspecific staining 
patterns a positive HER2 /Neu score of 2+ considered to be equivocal and is should be combined 
with ancillary techniques like fluorescent insitu hybridization to confirm the positivity. 
 Scores of 3+ is considered positive for HER2/Neu overexpression. Score of 0 and 1+ is 
considered negative. 
 
Artifacts interfering with IHC scoring of HER2/Neu 
1) Intestinal metaplasia 
2) Edge and crush artifacts 
3) Luminal staining 
                             Amplification of HER2/Neu is said to have more association with 
intestinal type of carcinomas. These patients have lowered rates of survival. HER2/Neu is 
gaining the reputation as one of the independent prognostic markers in gastric carcinomas. It 
stands next only to the lymph node status in predicting the prognosis.13  
The role of pathologist in confirming the immunoreactivity of the tumour is crucial. As 
with most of the drugs trastuzumab has its own disadvantage. The side effects of this drug 
include headache, nausea, fatigue, hypokalemia, hepatotoxicity, peripheral neuropathy, visual 
impairment, conjunctivitis.7 
 
 
Ki -67 12,32,33,34 
The term Ki 67 was coined from the German town of Kiel .Here an experiment was 
carried on 96 clones of mouse antibody. Ki 67 was the antigen that reacted with the clone 
numbered 67 and hence the name was derived.    
            The gene for Ki 67 is situated on chromosome10. Ki 67 is localized to the cell nucleus 
during the phase of G1,
 S G2 and mitosis of the cell cycle.It is related to ribosomal RNA 
transcription. It is a non histone protein that maintains the cell cycle. Ki 67 is predominantly 
located in the nucleus during the interphase. Later a majority of this protein moves to the surface 
of the chromosomes. 
This antigen is not expressed in the resting cells of the G0 phase. Hence it is used to 
determine the extent of cellular proliferation in a given population of cells. It also determines   
the tumour aggressiveness. 
Among the Ki 67 antibodies MIB1 is considered to be the most reliable marker in the 
proliferating cells. They are produced from myeloma cell line in mice fused with splenic cells of 
mice that has been immunized with Ki 67 antigen. 
The other proliferation markers used in tumours are PCNA, AgNORs and techniques 
using incorporation of labeled nucleotide probes like titrated thymidine or bromodeoxyuridine. 
According to literature a remarkable co relation was obtained between expression of Ki 67 and 
the degree of tumour differentiation.  
It was also shown to have a positive co relation with the TNM staging. In spite of this the 
role of Ki 67 in being considered an independent prognostic marker in gastric carcinomas is 
questionable. 
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OBSERVATION AND RESULTS 
OBSERVATION AND RESULTS     
 
 
I.       INCIDENCE  OF  GASTRIC  CARCINOMAS : 
 
          This study was carried out in the Department Of Pathology Thanjavur Medical College  
 
From July 2012 to June 2014. The specimens were received from the Department of Surgery and  
 
Gastroenterology. A total of 260 specimen including both endoscopic biopsies and gastrectomy  
 
Specimens were received. 
 
                    Benign lesions such as tissues with normal study, chronic gastritis, ulcers,  
 
Non neoplastic polyps,intestinal metaplasia, inadequate material, and lesions within 5cm from  
 
the oesophagogastric junction where excluded from this study. The remaining 140  malignant  
 
lesions were included in the study.  They included 50  Gastrectomy specimens and 90 
 
Endoscopic biopsies. 
 
 
TABLE 1 : INCIDENCE OF GASTRIC CARCINOMAS AMONG OTHER 
 
CARCINOMAS IN THANJAVUR MEDICAL COLLEGE 
 
 
S.NO TIME PERIOD 
TOTAL NO.OF 
MALIGNANCIES 
NO. OF GASTRIC 
CARCINOMAS 
1. JULY 2012 – DEC 2012 525 37 
2. JAN  2013 – JUNE 2013 550 25 
3. JULY 2013 – DEC 2013 502 43 
4. JAN 2014 – JUNE 2014 488 35 
TOTAL 2065 140 
INCIDENCE RATE OF GASTRIC CARCINOMAS  -  6.78% per 1000 malignancies 
 
 
CHART 1 : INCIDENCE OF GASTRIC CARCINOMA IN THIS STUDY
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TABLE  2 :  YEARLY  INCIDENCE  OF  GASTRIC  CANCER  IN  T
S.NO 
1. JULY 2012 
2. JAN 2013 
3. JULY 2013 
4. JAN 2014 
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TABLE 3: AGE WISE INCIDENCE OF GASTRIC CARCINOMA IN THANJAVUR 
 
MEDICAL COLLEGE 
 
S. NO AGE NO. OF CASES 
1. 20 -29 1 
2. 30 -39 9 
3. 40 -49 20 
4. 50 – 59 48 
5. 60 -69 46 
6. >70 16 
TOTAL 140 
 
 
 
Of the total number of malignancies the age group that was most affected is   people  in 
their fifth and sixth decade of life. The maximum number of cases 48 was observed in the age 
group 50 -59. This is closely followed by 46 cases in individuals in age group of 60 -69. The 
incidence was the least in   individuals below the age group of 30 years. 
 
 
 
 
 
CHART  3 : AGE WISE INCIDENCE OF GASTRIC CARCINOMAS
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TABLE 4 : SEX  WISE  INCIDENCE  OF  GASTRIC  CARCINOMA
TOTAL CASES
140 
CHART 4 : SEX WISE INCIDENCE OF GASTRIC CARCINOMA
 
Among the total cases of gastric carcinoma 102 cases were of the male sex constituting 
 
  70% . The females cases formed the remaining 30% with  39 cases.
SEX INCIDENCE OF GASTRIC CARCINOMAS
 
 MALE FEMALE 
101 39 
 
 
 
 
 
 
MALE
70%
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TABLE 5 : LESIONS  IN  ENDOSCOPIC  BIOPSY  SPECIMENS  MALE 
 
 
S.NO LESION CASES 
1. CHRONIC GASTRITIS 12 
2. ULCER 18 
3. INTESTINAL METAPLASIA 1 
4. DYSPLASIA 6 
5. CARCINOMA 58 
6. NORMAL STUDY 24 
7. NIL TISSUE 8 
TOTAL 127 
 
 
 
Of the 127 endoscopic biopsy samples from male patients 58 cases were positive for 
carcinoma. 24 cases showed normal study. 18 cases were reported as ulcer with granulation 
tissue. 12 cases were reported as chronic gastritis. 8 samples were inadequate. 6 cases showed 
dysplastic changes. 
 
 
 
  
CHART 5 : ENDOSCOPIC BIOPSIES IN MALE
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TABLE  6 : LESIONS
 
S. NO 
1. 
2. 
3. INTESTINAL METAPLASIA
4. 
5. 
6. 
7. 
 
 
Of the 45 endoscopic biopsy samples from female cases 18 showed malignancy. 7 cases 
were reported as chronic gastritis. 9 
samples were inadequate. 1 case showed dysplastic changes.
CHART  6: LESIONS  IN  ENDOSCOPIC  BIOPSY  FEMALE
18, 40%
5, 11%
  IN ENDOSCOPIC  BIOPSY   FEMALE
LESIONS CASES
CHRONIC GASTRITIS 7
ULCER 9
 1
DYSPLASIA 1
CARCINOMA 18
NORMAL STUDY 5
NIL TISSUE 4
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cases were ulcer. 5 cases showed normal histology. 4 
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TABLE 7 : GASTRIC CARCINOMAS IN ENDOSCOPIC BIOPSIES AND
 
PROCEDURE 
ENDOSCOPIC BIOPSY
GASTRECTOMY
 
                      Of the total samples studied 50 were gastrectomy specimens. This included partial,
 
 subtotal and total gastrectomies. 90 were endoscopic biopsies.
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TABLE 8 : LOCATION OF GASTRIC CARCINOMAS
 
LOCATION
CARDIA
BODY
ANTRUM
PYLORUS
DIFFUSE GROWTH
 
 
           In this study it was observed that most of the malignant tumou
 
with a total of 84 cases constituting around 60 %  followed by the body of the stomach with 30
 
Cases. The occurance of tumours in the proximal stomach is the least with only 5 cases forming 
 
3.57%.  Hence the occurance of mali
 
to the proximal regions of stomach.
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TABLE 9 : CLASSIFICATION OF GASTRIC CARCINOMA ACCORDING TO
WELL 
20 
 
 
Majority of cases were reported as moderately differentiated adenocarcinoma with a total 
of 69 cases. 37 cases were poorly differentiated. 20 cases were well differentiated.
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TABLE 10 :  W.H.O. CLASSIFICATION OF GASTRIC CARCINOMAS
S.NO TUMOUR TYPE
1. TUBULAR ADENOCARCINOMA
2. PAPILLARY ADENOCARCINOMA
3. MUCINOUS ADENOCARCINOMA
4. POORLY COHESIVE CARCINOMA(SIGNET RING)
5. ADENOSQUAMOUS CARCINOMA
6. LOW GRADE DYSPLASIA
7. HIGH GRADE DYSPLASIA
 
              In this study 117 cases were reported as Tubular adenocarcinoma. 5 cases as mucinous 
  
adenocarcinoma. 8 cases were reported as poorly cohesive carcinoma containing signet ring 
 
cells. 1case of papillary adenocarcinoma and 2 cases of adenosquamous carcinoma were reported
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TABLE 11 : CLASIFICATION OF GASTRIC CARCINOMAS ACCORDING TO
 
 
 
 
 Of the total cases 125 cases were reported as intestinal type of adenocarcinoma & 8 cases 
were reported as diffuse type of carcinoma according to the Lauren’s classification.
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TABLE 12 : EXTENT ON INVASION BASED ON TNM STAGING
 
S.NO EXTENT OF PRIMARY TUMOUR(T)
1. 
2. 
3. 
4. 
5. 
6. 
 
In this study 18 cases showed tumour
followed by 13 cases showing invasion into the visceral peritoneum constituting 26%. Early 
gastric carcinomas formed 20% of cases with a total of 10 cases. One case showed tumour 
involving the adjacent structures (2%) (Appendix IV)
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TABLE 13: LYMPH NODE STATUS BASED ON TNM CLASSIFICATION
 
S. NO LYMPH NODE STATUS
1. 
2. 
3. 
4. 
5. 
          
    In this study the majority of cases showed no nodal involvement , namely 24 cases(48%),
 
Closely followed by cases with N2 status, 14 cases (28%). 20% of the tumours showed N1 
 
Status and 2 cases (4%) are of N3a status, none of the cases were positive for N3b. (Appendix 
 
IV) 
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  IMMUNOHISTOCHEMISTRY – HER 2 EXPRESSION 
 
          
S.NO 
PATH 
No. 
GRADE OF DIFFERENTIATION 
HER 2 
GRADE 
1. 2315/12 POORLY DIFFERENTIATED ADENOCARCINOMA 1+ 
2. 3405/12 MODERATELY DIFFERENTIATED ADENOCARCINOMA 0 
3. 588/13 POORLY DIFFERENTIATED ADENOCARCINOMA 0 
4. 938/13 POORLY DIFFERENTIATED ADENOCARCINOMA 1+ 
5. 1397/13 MODERATELY DIFFERENTIATED ADENOCARCINOMA 2+ 
6. 2960/13 POORLY DIFFERENTIATED ADENOCARCINOMA 0 
7. 3118/13 WELL DIFFERENTIATED ADENOCARCINOMA 0 
8. 3227/13 MODERATELY DIFFERENTIATED ADENOCARCINOMA 0 
9. 3265/13 PAPILLARY ADENOCARCINOMA 3+ 
10. 3271/13 MODERATELY DIFFERENTIATED ADENOCARCINOMA 0 
11. 3281/13 SIGNET RING CELL CARCINOMA 0 
12. 3719/13 MODERATELY DIFFERENTIATED ADENOCARCINOMA 0 
13. 230/14 WELL DIFFERENTIAED ADENOCARCINOMA 0 
14. 298/14 WELL DIFFERENTIATED ADENOCARCINOMA 2+ 
15. 329/14 MODERATELY DIFFERENTIATED ADENOCARCINOMA 0 
16. 624/14 POORLY DIFFERENTIATED ADENOCARCINOMA 0 
17. 864/14 WELL DIFFERENTIATED ADENOCARCINOMA 1+ 
18. 974/14 WELL DIFFERENTIATED ADENOCARCINOMA 0 
19. 1002/14 POORLY DIFFERENTIATED ADENOCARCINOMA 0 
20. 1147/14 WELL DIFFERENTIATED ADENOCARCINOMA 3+ 
21. 1160/14 WELL DIFFERENTIATED ADENOCARCINOMA 0 
22. 1203/14 WELL DIFFERENTIATED ADENOCARCINOMA 1+ 
23. 1237/14 WELL DIFFERENTIATED ADENOCARCINOMA 0 
24. 1414/14 POORLY DIFFERENTIATED ADENOCARCINOMA 0 
25. 1735/14 MODERATELY DIFFERENTIATED ADENOCARCINOMA 0 
 
                  25 cases in this study were chosen for immunohistochemical analysis. This included 
gastrectomy specimens and reported as tubular adenocarcinoma, papillary adenocarcinoma and 
signet ring cell carcinomas. IHC grading of 0 and 1+ is considered negative, 2+ is considered 
equivocal and 3+ is considered positive.  Chi square =2.701 p>0.05. Not significant. There is 
no association between the grade and HER2 levels. 
 
 
 
 
 
TABLE 14 : HER 2 EXPRESSION IN VARIANTS OF GASTRIC CARCINOMA
S.NO TYPE OF CARCINOMA
1. TUBULAR (G1)
2. TUBULAR (G2)
3. TUBULAR (G3)
4. PAPILLARY VARIANT
5. 
SIGNET RING CELL 
CARCINOMA 
 
      In this study out of 25 cases only 2 cases showed 3+ positivity (8%) , 2 cases showed 
equivocal grading (8%) and 21 cases showed negative 
Tumours with signet ring cell morphology showed a negative scoring. 
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POSITIVE
EQUIVOCAL
NEGATIVE
IMMUNOHISTOCHEMISTRY- KI 67 
 
 
S.NO PATH NO 
AGE/
SEX 
GRADE OF DIFFERENTIATION 
Ki 67 
Score 
1. 2315/12 65/M POORLY DIFFERENTIATEDADENOCARCINOMA 60% 
2. 3405/12 55/M MODERATELY DIFFERENTIATED ADENOCARCINOMA 20% 
3. 588/13 60/M POORLY DIFFERENTIATED ADENOCARCINOMA 60% 
4. 938/13 65/M POORLY DIFFERENTIATED ADENOCARCINOMA 10% 
5. 1397/13 55/F MODERATELY DIFFERENTIATED ADENOCARCINOMA 30% 
6. 2960/13 40/F POORLY DIFFERENTIATED ADENOCARCINOMA 30% 
7. 3118/13 75/M WELL DIFFERENTIATED ADENOCARCINOMA 10% 
8. 3227/13 50/F MODERATELY DIFFERENTIATED ADENOCARCINOMA 60% 
9. 3265/13 50/M PAPILLARY ADENOCARCINOMA 15% 
10. 3271/13 35/F MODERATELY DIFFERENTIATED ADENOCARCINOMA 70% 
11. 3281/13 70/F SIGNET RING CELL CARCINOMA 30% 
12. 3719/13 65/F MODERATELY DIFFERENTIATED ADENOCARCINOMA 50% 
13. 230/14 60/M WELL DIFFERENTIAED ADENOCARCINOMA 15% 
14. 298/14 60/M WELL DIFFERENTIATED ADENOCARCINOMA 50% 
15. 329/14 62/F MODERATELY DIFFERENTIATED ADENOCARCINOMA 30% 
16. 624/14 60/M POORLY DIFFERENTIATED ADENOCARCINOMA 70% 
17. 864/14 70/F WELL DIFFERENTIATED ADENOCARCINOMA 60% 
18. 974/14 60/M WELL DIFFERENTIATED ADENOCARCINOMA 70% 
19. 1002/14 44/F POORLY DIFFERENTIATED ADENOCARCINOMA 20% 
20. 1147/14 55/M WELL DIFFERENTIATED ADENOCARCINOMA 40% 
21. 1160/14 52/F WELL DIFFERENTIATED ADENOCARCINOMA 10% 
22. 1203/14 52/M WELL DIFFERENTIATED ADENOCARCINOMA 20% 
23. 1237/14 35/M WELL DIFFERENTIATED ADENOCARCINOMA 20% 
24. 1414/14 45/M POORLY DIFFERENTIATED ADENOCARCINOMA 10% 
25. 1735/14 45/F MODERATELY DIFFERENTIATED ADENOCARCINOMA 50% 
 
         The  Ki 67 labelling index was obtained for 25 cases including 23 cases of tubular 
adenocarcinoma, 1 case of papillary adenocarcinoma and 1 case of signet ring cell 
adenocarcinoma.  The mean value was calculated to be 36.4%.  Hence tumours with proliferation 
index <36.4%were categorized as low and >36.4% were categorized as high proliferative 
activity. Chi square = 0.4. p> 0.05. Not significant. There is no association between the 
grade and Ki 67 expression. 
 
 
 
 
TABLE 15: KI 67 INDEX IN GASTRIC CARCINOMA
GRADE 
G1 
G2 
G3 
         
   In  this study the number of tumours with a high proliferation index was 11, when compared to  
12 cases with a low proliferation index. The average proliferation index for well differentiated 
tumours is 32.78%, for moderately differentiated tumours it is 44.28%, poorly differenti
tumours have an average proliferation index of  37.14%.
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Figure 1: 1505/14- Gastrectomy specimen. Reveals an ulceroproliferative growth 
measuring 5x4 cm in the antrum. Adjacent mucosa ironed out. c/s of the growth grey white. 
 
 
 
Figure 2: Partial gastrectomy specimen with an ulcerated growth measuring 4x3 cm 
located in the antrum. c/s- The growth grossly extends upto the serosa. 
 
Figure 3:1414/14:  Gastrectomy specimen showing superficially ulcerated plaque. It is 
accompanied by Conspicuous thickening of gastric wall. Adjacent mucosa ironed out. 
 
 
 
Figure 4 : 2315/12  Total Gastrectomy specimen with a growth measuring 15x 10 cm 
involving almost the entire stomach.The growth is nodular with focal areas of ulceration. A 
portion of large intestine was attached to the stomach. 
 
 
 
Figure 5: 230/14 – Well differentiated adenocarcinoma. H/E section shows a tumour 
composed of  malignant cells in a predominantly glandular pattern invading the 
submucosa.(Scanner View) 
 
 
 
Figure 6: 230/14  - Tumour is composed of predominantly malignant glands in a tubular 
pattern showing irregular budding, branching and anastamosis.(10x) 
 
 
 
Figure 7: 230/14- Malignant glands are lined by cuboidal to columnar cells with a  
pseudostratified, pleomorphic vesicular nucleus with prominent nucleoli exhibiting loss of 
polarity. (40x) 
 
 
 
Figure 8: 3724/13 – Moderately differentiated adenocarcinoma. Tumour is composed of 
glandular component admixed with solid sheets of neoplatic cells. (10x) 
 
 
 
Figure 9: 3724/14-  Moderate differentiated  adenocarcinoma. The neoplastic glands are 
lined by cuboidal cells with  basally situated  pleomorphic vesicular nucleus with loss of 
cytoplasmic mucin 
 
 
 
Figure 10: 624/14- Poorly  differentiated adenocarcinoma. Composed of neoplastic cells 
arranged predominantly in a solid pattern with sparse glandular elements.(40x) 
 
 
 
Figure 11: 624/14- Poorly differentiated adenocarcinoma. Tumour is composed of  poorly 
cohesive cells predominantly in a dispersed pattern.  Malignant cells are seen  infiltrating 
the     muscularis propria.(10x) 
 
 
 
Figure 12:624/14- Poorly differentiated adenocarcinoma. Composed predominantly of 
sheets of dispersed cells having a vesicular pleomorphic nucleus infiltrating between the 
muscle bundles.(40x) 
 
 
Figure 13: 814/14 – Mucinous adenocarcinoma. Tumour is characterized by copious 
amount of extracellular mucin forming >50% of the tumour volume. 
 
 
 
Figure 14: 814/14- Mucinous adenocarcinoma showing clusters of malignant cells 
exhibiting pleomorphism and hyperchromasia floating in pools of mucin. (40x) 
 
 
 
          
 
Figure 15, 16, 17. 1505/14- Adenosquamous Carcinoma. The tumour is composed of an 
admixture of varying proportion of adenocarcinoma and squamous cell carcinoma. The 
squamous component forms >25% of the tumour volume. The squamous component shows 
malignant keratin pearl formation. 
 
 
Figure 18: 1147/14- HER2 Score 3+ Well differentiated adenocarcinoma showing Intense 
staining with HER2. 
 
 
 
Figure 19: 1147/14-. HER2 score- 3+  Malignant glands showing complete and strong 
membrane positivity 
 
 
Figure 20: 3265/13- HER2 Score 3+: well differentiated adenocarcinoma showing 3+ 
membrane positivity in >10% of tumour cells.(10x) 
 
 
 
Figure 21: 3265/14 – HER2 score of 3+ : Malignant glands showing  complete/Basolateral 
membrane positivity. 
 
 
 
Figure 22: 1203/14 HER2 Score 2+ :  Well differentiated adenocarcinoma showing  HER2 
score of 2+.(10x) 
 
 
 
Figure 23: 1203/14- - HER2 Score 2+ :  Weak to moderate complete or basolateral/ 
cytoplasmic membrane positivity in 10% of tumour cells. (40x) 
 
 
 
Figure 24:  1237/14 : HER2 score 1+ : well differentiated adenocarcinoma showing IHC 
score of 1+.(10x) 
 
 
 
Figure 25: 1237/14- HER2 Score 1+ : Faint cytoplasmic membrane positivity in 10% of the 
cells.  
 
 
 
Figure 26 : 2315/13 – HER2 Score 0- No membranous reactivity in the Malignant epithelial 
cells. 
 
 
 
 
Figure 27 : 230/14 – HER2 score 0 – No membranous reactivity in the tumour cells.(40x) 
 
 
 
Figure 28  : 588/13 – Poorly differentiated adenocarcinoma showing high Ki 67 
expression.(10x) 
 
 
 
Figure 29: 588/13- Malignant epithelial cells showing strong nuclear positivity of Ki 67. 
(40x) 
 
 
Figure 30: 1203/14 – Well differentiated adenocarcinoma  with malignant glandular 
elements showing low Ki 67 expression.(10x) 
 
 
 
Figure 31: 1203/14- Nucleus exhibiting  Ki 67 positive cells lining the glandular epithelium. 
(40x). 
 
 
Figure 32: 974/14 :  Well differentiated adenocarcinoma. Nucleus of  malignant glandular 
epithelium  showing  strong nuclear positivity of   Ki 67.(40x) 
 
 
Figure 33: 1203/14- Well differentiated adenocarcinoma showing strong nuclear 
positivity.(10x) 
 
 
 
Figure 34: 3281/13 : Signet Ring cell carcinoma  Composed predominantly of single cells  
or isolated cells. The cells have a prominent intracytoplasmic mucin vacuole  and an 
eccentrically placed hyperchromatic nucleus.(40x) 
 
 
Figure 35 : 3281/ 13  Signet Ring cell carcinoma Stained with Periodic Acid Schiff. The 
tumour is composed of individual cells separated by a fibrous stroma (10x) 
 
 
 
 
 
 
 
 
Figure 36 & 37: 3069/13 – Signet Ring cell carcinoma. (40x)- Periodic acid Schiff 
demonstrates intracytoplasmic mucin vacuole that has taken up the magenta stain.(40x) 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
DISCUSSION 
DISCUSSION 
 
 
Gastric carcinoma ranks among the top five cancers of the world. Its  the fourth most 
common cancer in terms of incidence. It is the second biggest killer among all cancers. 
    According to Inoue et al40 stomach cancer stands fourth among the major killers. It 
stands  next  to  cancer of lung, breast and colorectum with its incidence of 9% . It closely 
follows lung cancer as the second most important killer (10%). 
It has been estimated that by the year 2020 the world population would exceed 75 
million. Among this nearly 15 million individuals would be affected by cancer. There will be a 
cancer related mortality of 12 million40. A phenomenon referred to as “The unplanned triumph” 
has emerged in the field of gastric cancer. It is the widespread decrease in incidence in the last 50 
years. Inspite of all this cancer of stomach continues to rank among the top five important killers. 
According to a study in Australia, known for its low incidence and prevalence, gastric 
carcinoma the disease remains to be the sixth leading cause of death. A study carried out in USA  
has reported an incidence of 7.3/100000 in males and 3.6/100000 in case of its female 
population38. 
Japan was once considered as the world leader in gastric carcinoma. It showed a change 
in trend with the lung cancer being the prime killer in men and colorectal cancer in women3. 
Katherine et al41 reported two third of the gastric carcinomas occurred in the developing 
countries of the world. Countries like Japan and Korea form the biggest contributers. 
According to NCIN data base people of Indian ethnicity have lowered rates of cancer 
incidence when compared to the natives of England42. India  known for its diversity in culture. 
Diet and ethnicity also play a role with a diverse presentation in its cancer statistics. According 
to the reports submitted by the 10th International gastric cancer congress, incidence of gastric 
carcinoma among Indian male is 11.8/100000 and among Indian females it is 5.9/100000. The 
mortality rates in male  is 3.9/100000 and in females it is 2.1/10000043. 
Malhotra et al states that South Indian regions ranks first in the incidence of gastric 
carcinoma. It has the highest incidence   when compared to the other regions of India44. 
The state of Mizoram was not included in the in the National Cancer Registry Programme till 
2003.  According to recent statistics it is said to have the highest prevalence in India45. 
          A study by Imran Ali et al35 states that maximum mortality in India is attributed to cancer. 
It causes nearly 0.3 million deaths every year, next to cardiovascular disorders. The annual 
prevalence was estimated to be around 2.5 million cases with the number of newly diagnosed 
cases being around 8,00,000. The number of cancer deaths being around 50,000 per year. 
Prevalence of gastric carcinoma is high in Mizoram and regions of north east India. Gastric 
carcinoma is the second most commonly reported malignancy in the states of Tamil Nadu, 
Andhra Pradesh, Sikkim and Goa. It is the third most common cancer in the state of Jammu and 
Kashmir.  
              The incidence of Gastric carcinoma in our study carried out in Thanjavur medical 
college is 6.78% .It assumes fourth position following carcinomas of head and neck region, 
colorectum and breast. It is consistent with  most of the world statistical reports. The incidence of 
Gastric carcinoma in AIIMS, New Delhi is 2.8% and it assumed the 11th position46.  
  
 
 
 
 
TABLE 16: INCIDENCE OF GASTRIC CARCINOMAS  IN VARIOUS INSTITUTIONS  
ACROSS  INDIA47,48 
 
S. No NAME OF THE INSTITUTE MALE FEMALE 
1. 
KIDWAI MEMORIAL INSTITUTE OF 
ONCOLOGY ,BANGALORE 
7.0% 2.3% 
2. TATA MEMORIAL HOSPITAL , MUMBAI 2.5% 1.3% 
3. 
ASSAM MEDICAL COLLEGE , 
DIBRUGARH 
4.2% 4.1% 
4. 
ADAYAR CANCER INSTITUTE, 
CHENNAI 
9.1% 3.1% 
5. IN THIS STUDY 4.9% 1.9% 
  
                In this study the percentage of incidence of gastric carcinoma among all cancers in our 
institute is 4.9% in males and 1.9% in females. This is compared with the data from the major 
tertiary care centres across India . The Adayar cancer institute Chennai reports an incidence of 
9.1% of cases in males and 3.1% cases in females. The Tata memorial hospital of Mumbai  
reports 2.5% of cases in males and 1.33% of cases in females. Kidwai institute of oncology 
Banglore show a statistics of 7% in males and 2.3% in females. Assam medical college has an 
incidence of 4.2% in males and 4.1% in females. 
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According to the AIIMS statistics gastric carcinoma is the ninth leading cause of cancer 
death in males (3.5%) and the assumes the 13th position in cancer deaths among females (1.9%)46 
                     The data given by the Mumbai cancer registry states that the annual age adjusted 
incidence rate for gastric carcinoma among men was 4% with about 1/ 337 individuals having 
the chance of developing cancer in his lifespan49. The annual incidence rate in men is 4.2%   and 
in women is 2.2% with a mortality rate of 2.5% in male and 1.9% in female. 
           Roder et al38 states that the male female ratio in gastric carcinoma was 1.8:1. This was 
reported in a study carried out in Centre for Cancer control and Research, Australia.                  
                 Most of the studies carried out in gastric carcinomas usually concentrate in urban & 
semi urban statistics. A study was carried out by Rajaraman et al in the Dindugal Ambilikai 
cancer centre which is a rural based population registry. Here the reported incidence in the male 
population was 5.6% and the female population was 2.5%. This is low when compared to the 
statistics from Chennai in the same year which was 11.1% for males and 5.3% for females.51 
Inspite of decreased incidence of   this population had a decreased survival when compared with 
urban population. This is attributed to the lack of early screening and diagnostic facilities, 
availability of interventional practices and compliance of the patients to the treatment regimens. 
AGE WISE INCIDENCE OF GASTRIC CARCINOMA 
              In our study the prevalences of gastric carcinoma in various age groups were analysed. 
It was found to be highest in the fifth to sixth decade of life (34.28%). This is closely followed 
by a prevalence of 32.28% in individuals in the age group of 60 - 69. The incidence is least in 
individuals under the age of 30 yrs. Our data correlates with the world statistics and the statistics 
of the leading tertiary care Institutes of India. 
 
TABLE 17 : AGE WISE COMPARISON OF GASTRIC CARCINOMA AMONG 
VARIOUS TERTIARY CARE CENTRES 
 
AGE  
IN  
YEARS 
AIIMS,NEW DELHI THANJAVUR MEDICAL 
COLLEGE 
NO. OF 
CASES 
% OF CASES NO. OF CASES % OF CASES 
<29 7 2.83% 1 0.7% 
30 – 39 24 9.71% 9 6.42% 
40 – 49 43 17.40% 20 8.07% 
50 -59 62 25.10% 48 34.28% 
60 -69 57 23.07% 46 32.85% 
>70 54 21.86% 16 11.42% 
 
   The statistics regarding the predominant age of incidence co related with the statistics of 
AIIMS, New Delhi. There the predominant age group affected was people in their fifth & sixth 
decade of life with 25.10% & 23.07% respectively. All studies showed the lowest incidence rate 
in individuals less than the age group of 29 years. 
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                   Malhotra et al44 compares  regional differences and  age group of individuals with 
gastric cancer  in India. According to him the onset of gastric cancer  in people of south India 
starts  around 35 -55 years. This is a decade earlier when compared to  the age  of 45 -55 years in 
the people of Northern territory.  This was postulated to have occurred by the influence of the 
local diet on carcinogenesis. 
                    Sipponen et al52 compares the age of incidence with the sex. According to the study 
carried out in a Finnish Cancer Registry, the female population presented with a delay of around 
10 -15 years when compared to males. This was mainly attributed to the protective effects of the 
harmone oestrogen. They also have a tendency to acquire H.Pylori infection later in their life 
time. 
                 Studies carried out by Matley et al53 states that carcinoma stomach occurring in young 
individuals posses certain specifications. They predominantly are of diffuse type, with signet ring 
morphology often affecting the female sex. They shows minimal association with intestinal 
metaplasia. They have increased propensity to occur in the proximal stomach.  
          A study by Kshitiz Ranka et al54 states that the predominant age & sex affected by stomach 
cancer is men in their 5th decade of life. Kalyani et al55 studied the spectrum of gastric cancer in 
the Kolar district of Karnataka for a period of ten years. She concluded that the common 
malignancy among gastrointestinal tract was that of stomach. Maximum incidence was observed  
in 7th decade in males and  6th decade in females. This was in contrast to some studies which 
advocated late incidence in females. 
 
 
 
 
TABLE 18 :COMPARISON OF MEAN AGE OF OCCURE
STUDY 
Shimoda et al
Ichikawa et al
Ajani et al58
Aarnio et al
In this study
 
      The mean age of occurrence in this study is 55.3 years. The youngest age of occurrence was 
28 years and the oldest age of occurrence in this 
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  SITE OF INCIDENCE: 
             Most cases are located in the lower portions of the stomach mainly the pyloric antrum . 
Inoue et al40 states that of all cases of gastric carcinoma only 15 % are situated in proximal 
stomach. 
             In another study Roder et al38 reports an incidence of 31.7% of proximal gastric cancers 
in male and 18.8% of cases in females. The high risk regions of the world has a predilection to 
develop carcinomas in antrum and pylorus. In the low risk regions the incidence of proximal 
gastric cancers are found to be increasing60. 
 
TABLE 19: COMPARISON OF THE SITE OF OCCURRENCE OF GASTRIC 
CARCINOMAS IN VARIOUS STUDIES  
STUDY UPPER MIDDLE LOWER 
DIFFUSE 
THICKENING 
Vidyavathi et al61 3 (6.25%) 13 (27.08%) 32 (66.66%) 0 
Takashi et al91 64(10.11%) 280(44.23%) 225(35.54%) 64(10.11%) 
Athanarsios et al85 28(25.45%0 51(46.36%) 31(28.18%) 0 
In this study 5(3.75%) 30 (21.43%) 100 (71.4%) 5 (3.57%) 
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incidence of distal tumours. Distal tumours are the predominant subtype occurring in Japan. The 
incidence of proximal cancers in Japan is increasing. This is attributed to the westernization of 
food culture. 
           In our study the tumours of the distal portions of the stomach constituted the majority of 
lesions with around a 100 cases (71.4%) which correlates with most of the studies.
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COMPARISON OF THE HISTOLOGICAL CLASSIFICATION
 
TABLE 20 :COMPARISON BAS
Study 
Pentti et al. 62 
Pekka et al.63 
Tanner et al.31 
Gravelos et al.11 
In this study 
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              In this study the number of cases presenting with the Lauren’s intestinal type is 125 
constituting 89.28%.  8 cases come under the diffuse type of tumours constituting 5.71%. 
                       Various classification systems have been put forth in studying gastric carcinomas. 
The most commonly used is Lauren’s and WHO classification. 
                     Pentti et al62 states that in a comparative study between cases and controls intestinal 
metaplasia was common in malignant cases. It was around 42% when compared to non 
malignant counterparts (23%). 
                      In a study of gastric cancer occurring in HNPCC syndrome patients, Aarnio et al59    
states that intestinal type gastric carcinoma had more positive co relation with chronic gastritis 
associated with H.pylori infection when compared to diffuse carcinomas. 
                    A time trend study was carried out in high and low risk areas by Pekka et al63. It 
observed   that during the initial time period of the study the ratio of intestinal and diffuse type of 
carcinoma was 1:7. This was followed by a gradual transition resulting in a ratio of 1:3 twenty 
years later. This transition said to be due to increase in cases of intestinal carcinoma. 
                                          In a study analyzing the gastric carcinoma of young Tso et al70 
observed that the tumours were predominantly of diffuse type. These diffuse carcinomas cases 
occurred predominantly in females. Most of the patients had reduced survival rates. 
         In his study Si Chun Ming71 states that the survival in patients with intestinal type 
carcinoma is more when compared to patients with diffuse type carcinoma. 
 
 
 
 
 
TABLE 21 : COMPARISON BASED ON WHO CLASSIFICATION
WHO 
CLASSIFICATION 
TUBULAR
Emmanuelle et al89 14
Noriya et al64 129
In this study 117
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                          In this study, according to the W.H.O classification majority of the cases were of 
tubular adenocarcinoma constituting 117 cases (87.96%). This was followed by poorly cohesive 
variant of carcinoma predominantly of the signet ring cell type 8 cases (6.01%). 5 cases were 
mucinous adenocarcinoma (3.76%), 2 cases of adenosquamous carcinoma (1.5%) and one case 
of papillary adenocarcinoma(0.7%). Noriya et al64   reported 129 cases of tubular adenocarcinoma 
and 10 cases of papillary adenocarcinoma. 
 
 
TABLE 22 : COMPARISON BASED ON GRADE OF DIFFERENTIATION 
 
 
 
DIFFERENTIATION WELL MODERATE POOR 
Nobuyuki et al86 9 13 9 
Ferda et al76 7 5 4 
In this study 20 69 37 
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TABLE 23 : COMPARISON BASED
STUDY 
Yoshihide et al.65 
Takekazu Yamao66 
In this study 
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ed out in the cancer institute hospital of Tokyo in early 
67. compares differentiated and undifferentiated carcinoma. He 
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A tumours were more differentiated (81.3%) when compared to the penetrating type B tumours 
which had more of poor differentiation 
 
STAGING AND LYMPH NODE INVOLVEMENT 
 
        Takikazu et al66 states that one of the most important prognostic factor in early gastric 
carcinoma is the presence or absence of lymph node involvement. He states that the occurrence 
of nodal metastasis in early gastric carcinoma is rare. 
                        Noriya et al64 studied the clinical outcome of patients who underwent endoscopic 
mucosal resection for early gastric carcinoma. It was observed that the lymphatic involvement 
was seen in 1 case of carcinoma confined to mucosa and 13 cases with extension of carcinoma 
into the sub mucosa. The most significant determinant for lymph node metastasis in early gastric 
carcinoma was venous or lymphatic invasion. Increased lymph node metastasis was observed in 
case of papillary adenocarcinoma. 
                  Yoshihide et al65 in his study evaluated the E Cadherin expression in gastric 
carcinoma. He observed that cases with increased nodal metastasis and distant organ 
involvement had increased expression of E Cadherin. 
                Jurgen et al69 in a German gastric carcinoma study observed  that the prognosis was 
bad in gastric carcinoma if 20% of the resected nodes showed evidence of metastasis. He stated 
that the extent of lymph node dissection could be considered one of the independent prognostic 
factor in gastric carcinoma in addition to lymph node status, depth of invasion and residual 
disease. 
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HER 2 Neu  IN  GASTRIC CARCINOMA 
 
 
       10% of the world’s malignant tumour burden is contributed by gastric carcinoma.  
The vague and nonspecific symptoms presents majority of cases in an advanced stage. These 
tumours are often unresectable. In the modern treatment era, cancer is one disease where 
treatment regimens are tailored to suit the need of the individual patient. This includes an array 
of combination chemotherapy coupled with targeting the molecular basis of the disease 
pathogenesis.  
             Several molecular agents have been tested for the targeted therapy . They are Cetuximab, 
Matizumab, Panituzumab, Trastuzumab etc. They act via the Epidermal Growth Factor receptor.  
Gefitinib, Erlotinib and Lapatinib act as tyrosine kinase inhibitors. Other agents that can be used 
are matrix metalloprotease, Insulin like growth factor 1, fibroblast growth factor etc. 
                           The first drug that was used as a targeted therapy in gastric carcinoma was 
Trastuzumab. It got the approval of FDA in 2010. Evaluation of  expression of HER 2 in tissues 
is an important task. This view has also been supported by the ToGA trials. 
                  The family of Epidermal Growth Factor Receptors is formed by four members. They 
undergo activation by ligand binding. This results in homo or heterodimerization. Of all these 
receptors HER 2 is unique.It has a special conformation that makes it constitutively active. When 
over expressed it serves as the most likely binding partner to other receptors of same family. This 
initiates signal transduction that triggers uncontrolled cell proliferation. HER 2 over expression 
in Gastric carcinoma is said to have a positive correlation with shorter survival. In the ToGA trail 
the percentage of membrane over expression was 22.1% 
 
 
 
Specificities of HER 2 over expression in gastric carcinoma 
1. There is heterogenous distribution of HER 2 over expressing cells in gastric carcinoma. 
2. The expression of HER2 in gastric carcinoma is less when compared with  tumours of the 
oesophagogastric junction. 
3. HER2 over expression is more in intestinal type of carcinoma when compared to the 
diffuse type. 
According to the reports of Zhang et al HER3 over expression of 26.6% has been observed in 
diffuse carcinomas and dedifferentiated carcinomas. 
 
Importance of determining HER 2 positivity  
       The aim of determining the HER 2 status is not only to effectively implement the drug 
therapy that is costlier than the most conventional regimens but to effectively exclude the HER 2 
negative   individuals  because of the accompanying side effects of trastuzumab.  
        HER2 over expression with immunohistochemistry should be positively co related with 
FISH, CISH, RT- PCR. The extracellular domain of HER2 can be measured in the serum 
samples using ELISA technique.   
Factors influencing HER 2 expression in gastric carcinoma 
1. Fixative used 
2. Fixation time 
3. Thickness of the tissue slide 
4. Time interval between preparation and staining of sections 
5. Method used for antigen retrieval. 
6. Type of antibody used. 
7. Dilution of the antibody employed 
8. Temperature for incubation 
9. Time for incubation 
10.  Scoring system employed. 
           Alberello L et72 stated that the degree of correlation between HER 2 amplification 
and expression is less in gastric carcinomas. Around 20% of cases show amplification but no 
expression of the protein. These patients may not benefit from Trastuzumab. Hence IHC should 
always be the first line of investigation.  The role of the pathologist is crucial in selecting the 
therapy. They providing accurate and reproducible results. 
               Grabsch et al73 documented that 10% of the tumours showed a positive HER 2 
expression. Of these tumours 91% were of intestinal type. No appreciable co relation was 
observed between HER 2 status, staging and survival of patient. The study also reported 
prominent  intratumoral heterogenicity. These type of lesions have a propensity to produce false 
negative results when   HER2 testing is done on endoscopic biopsies. 
           BangYJ et al74  observed the mean standard survival rate was 18.6 months in a 
group of patients who received trastuzumab. This is compared to 17.1 months in a group who 
received chemotherapy alone. 
          Federica et al75  observed no significant correlation in the degree of over expression of 
HER2 with respect to the site, differentiation, pattern of growth and staging .According to this 
study IHC 0 to 1+ had a negative predictive value of 80 and a positive predictive value of 78.6. 
Of the 54 cases 49 cases were completely negative and out of the positive cases only 13 cases 
(24%) had homogenous expression. 
                          Jan Trost Jorgensen et al10 in his study analysed 42 publications 
regarding expression of HER2 in gastric carcinoma. 71% of the studies implied a positive 
corelation between HER2 overexpression and parameters like nodal involvement, serosal 
extension and distant metastasis. 
                     Gravalos et al11   observed that the expression of HER2 differed depending 
on histological type of tumour. HER2 expression was 16% for intestinal adenocarcinoma, 7% for 
diffuse type adenocarcinoma and not known for 14%. The HER 2 expression was 9.5% 
expression in tumours of stomach when compared to 25% expression of cancer in 
gastrooesophageal junction. 
       Tanner et al31 studied the HER 2 amplification in gastric carcinoma using 
Chromogenic in situ Hybridisation. It was documented that HER 2 expression was present in 16 
(12.2%) of the total 131 cases of gastric carcinomas. The HER2 amplification is more with 
intestinal type than the diffuse type. (21.5% vs 2%) 
         Josef Ruschoff et al13 reported HER2 positivity rate of 21% in gastric carcinoma when 
compared with tumours of gastro oesophageal junction. Co relation with fluorescent insitu 
hybridization in all 3+ cases showed 100% amplification when compared to 32% of 2+ cases and 
5% of 1+ cases. 497 cases were analyzed and 22.8% of the specimens showed HER 2 positivity. 
         Ferda et al76 observed 3+ HER2 positivity that accounted for 24% of the cases 
studied. The expression co related with the intestinal type of carcinomas. The HER2 expression 
was also increased in tumours in an advanced stage of 3 & 4. 
         Fusco et al77 observed that out of 292 cases studied 51 cases had a score of 2+ and 3+. 27 
cases had a score of 3+(8%). 29 cases had a score of 1+ and 212 cases had a score of 0 when 
their HER2 expression was analyzed comparing with nodal metastasis. 14% of cases were 
discordant with initial results. 22 cases that had a positive HER2 score in primary gastric cancer 
had a negative score in the nodes. Among the 126 cases of primary tumours that were HER2 
negative primary tumour 6 cases showed HER 2 positive lymph nodes. 
    Celick et al78 in his study observed that 11 out of 62 cases showed strong membrane 
positivity of 17.7% the increased expression was more in intestinal type carcinomas (24.3%) 
when compared to diffuse carcinomas exhibiting 4.76%. There was no co relation with the 
histological type, extent of invasion, size of tumour, nodal metastasis and HER2 expression. 
There was no relation between the proliferative activity and c-erb-2 expression. Hence it was 
concluded that c-erb-2 cant be used as a diagnostic marker in gastric carcinoma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 26 : COMPARISON OF HER 2 POSITIVITY IN VARIOUS STUDIES
STUDY 
Ayre Dursin et al78
Gravalos et al
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Josef Ruschoff et al13 in his study observed that out of 8 cases only 2 cases were HER2 
positive. 6cases were reported to be equivocal. In this study out of 25 cases 2 cases had HER 2 
positivity with a IHC score of 3+
of 0 or 1+ and were considered to be negative.
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TABLE  27 : COMPARISON OF HER2 SCORE WITH OTHER STUDIES
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ROLE OF Ki 67 IN GASTRIC CARCINOMA 
The proliferative activity of a tumour can be determined by various methods namely 
1. Cell cycle phase distribution using flow cytometric analysis. 
2. Cells in S – phase fraction using thymidine labeling index. 
3. Bromo deoxy uridine labeling index. 
4. Estimation of the mitotic activity. 
                         Each  techniques comes with its own disadvantage. Mostly the amount of 
material obtained would be small. The process of administering a mitogenic agent like 
bromodeoxyuridine and iododeoxyuridine is a time consuming and complex. The technique of 
flow cytometry to determine the proliferative activity may not be precise. This technique not 
only measures the proliferative activity of tumour cells. It takes into account the proliferative 
activity of the stromal cells, inflammatory cells such as the plasma cells and lymphocytes. 
           Yutaka yonemura et al80 states that Ki 67 labelling is quicker ,simple and more sensitive. 
It is compared to other techniques such as labeling with H. Thymidine or Bromodeoxyuridine.  
Ki 67 labelling does not require incubation of a fresh tissue sample. 
                 Ki 67 is a monoclonal antibody that reacts with the nuclear antigen. It is expressed 
throughout the the cell cycle, mainly in the late phase of G1, S, G2, and M. It is absent in the 
resting cells of the G0 phase. It is said to resemble the monoclonal antibodies of DNA 
polymerase. The Ki 67 positive cells are situated in and around the mucous neck zone in the 
normal gastric mucosa. 
                     Yoshihiro et al81 documented that tumours in advanced stage of pT3 and pT4 had 
elevated Ki 67 labelling index when compared to the tumours  in stage pT1 and pT2. 
Ki 67 expression was higher in tumours (>30.4%) with nodal metastasis and 
lymphovascular invasion. Tumours with increased metastatic potential had increased Ki 67 
expression when compared to tumours not going for a distant metastasis. Tumours in stage pT1 
and pT2 had a Ki 67 labeling index of <30.4% in 24 cases and >30.4% in 16 cases. Tumours 
with stage pT3 and pT4 had 19 tumours with Ki 67 activity of <30.4% and 32 tumours with a  Ki 
67 activity of more than >30.4%. 43 cases that had a proliferation index of >30.4% showed 
lymph node metastasis when compared to five cases with >30.4% labeling index having negative 
nodal involvement. Similarly vascular invasion was positive in 40 cases with a Ki 67 labelling of 
>30% when compared to 8 cases that had no vascular invasion.81 
      Rosa et al82 observed that the proliferative index of a gastric malignancies co related with 
both Ki 67 and Proliferating Cell Nuclear Antigen. PCNA is a 36 KD nuclear protein that is 
closely associated with the cell cycle. This gets expressed in the nuclei of cells in all phases of 
the cell cycle. It is produced in the late G1 and S phases. PC 10 is the monoclonal antibody that 
is produced against the genetically engineered PCNA. PCNA is an auxiliary protein of DNA 
polymerase δ. This was accidentally discovered when the auto antibodies in SLE reacted with 
them. 
                According to Rosa et al82 no significant co relation was obtained between PCNA 
expression and Ki 67 labeling. This could be attributed to the marked intertumoral 
heterogenicity, sample size ,tissue preparation techniques etc. The ability of PCNA to identify 
cells that has left the cell cycle recently because of its long half life and dysregulated expression 
of the DNA in malignancy. 
In his study Yonemura et al80 documented that high Ki 67 labeling index was found in 
65% of cases that had lymph node metastasis and in 33% of cases that did not have a nodal 
metastasis. 56% of advanced gastric tumours showed high Ki 67 labeling index when compared 
to 37% of cases with early gatric carcinoma. Well differentiated tumours showed 47% positivity 
when compared to 50% of poorly differentiated tumours. 72% of cases with increased Ki 67 
labeling index showed vascular invasion and 57% of cases showed positive lymphatic invasion. 
But no co relation was obtained between the degree of Ki 67 labeling and the gross morphology. 
                   Chen et al83 used a 10% cut off point for Ki 67 nuclear positivity to differentiate the 
patients with over expression and under expression. In his study over expression of Ki 67 was 
found in 74.42% of cases with survival of  43.31% for a period of three year and 35.94% 
survival for a period of 5 years. This was lower in individuals with a negative or a low Ki 67 
expression which was 77.27% for 5 years and 72.73% for 5 years. He states that the degree of 
over expression of Ki 67 in gastric carcinoma has Co relation with the grade, extent of invasion 
and clinical stage. It was found that tumours of stage III and IV showed higher expression of Ki 
67 proliferation index when compared to tumours in stage I and II. According to Chen et al83 Ki 
67 is a useful indicator in predicting the proliferative capacity of the tumour cells and also the 
extent of differentiation. 
                 Young Eun Joo et al84 in his study of 119 cases observed that the percentage of 
expression of Ki 67 ranged from 7.6% to 85.8%. The cut off point that was used to categorize the 
cases into high and low Ki 67 expression was obt     ained by calculating the mean and the mean 
valve of 49.5 was obtained. Accordingly 57 pateints were categorized in the group showing high 
expression and 62% of patients had low Ki 67 expression 
          Athanauio S et al85 in his study observed that increased Ki 67 labelling was observed in 
high grade tumours and tumours that had reached an advanced stage at the time of clinical 
presentation. According to his study tumours that had a Ki 67 expression of<5% and negative 
expression for Bcl 2 had higher survival rates when compared to Bcl 2 negative tumours with Ki 
67 expression of >5%. Ki 67 over expression is associated with poor survival and is considered 
to be one of the independent prognostic factors in his study. 
                      Dursun et al78 studied the expression of c-erb and Ki 67 in patients with gastric 
carcinomas. He documented that no significant correlation was obtained between the degree of c-
erb expression and the proliferative activity documented by Ki 67 labeling. 
              Nobuyuki Igarashi et al86 stated that patients with advanced gastric cancer had higher  
Ki 67 labeling index when compared to the mean value of 38.3%. 
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SUMMARY 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
 
         This study was done in the Department of Pathology, Thanjavur Medical College from the 
period of July 2012 to June 2014. 260 samples were received including both endoscopic biopsies 
and gastrectomy specimens. Using the exclusion criteria only 140 samples were included in this 
study. The results of  this study is summarized as follows: 
 The incidence rate of gastric carcinomas in this study is 6.78/1000 cases. 
 The most commonly affected age group is 50 -60 years constituting 34.28% 
 Males are more commonly affected than females with the male female ratio of 2.3:1. 
 Out of 127 endoscopic biopsies in male frank malignancy was reported in 45.6% of 
cases. 
 Out of 45 endoscopic biopsies in female frank malignancy was reported in 40% of cases. 
 The most common site of malignancy in this study is the gastric antrum. Around 60% of 
malignant lesions were localized here. 
 The least common site of gastric malignancy is the cardia constituting only 3.57% of 
cases in that location. 
 The most common subtype of malignancy according to the WHO classification is the 
Tubular adenocarcinoma. (83.57%) 
 The most commonly observed microscopic subtype, according to Lauren’s classification 
is the intestinal type adenocarcinoma (89.28%) 
 Most of the tumours have extended to the muscularis layer at the time of surgical 
resection (36%) 
 Majority of the cases showed no nodal involvement (48%) 
 Out of 25 case studied for Immunohistochemistry HER 2 positivity was seen in 2 cases 
(8%).HER2 scoring of 3+ was seen predominantly in well differentiated type of intestinal 
adenocarcinoma. 
 Out of 25 cases analyzed for Ki 67 expression, 52% of cases had low Ki 67 index . High 
Ki 67 expression was seen in 48% of cases. 
 There was no significant co relation observed between the grade of differentiation and the 
proliferation index. 
LIMITATIONS OF THIS STUDY 
 Open to selection bias. 
 Small sample size. 
 Limited information regarding clinical details and follow up. 
 Potential for deterioration of antigenicity in the samples for IHC due to long period of 
storage. 
 Inter observer variation in interpretation of IHC results. 
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CONCLUSION 
 
 
                                    Gastric carcinoma is one of the most devastating malignancies of the 
world. Its incidence has been reported from time immemorial. It still continues its reign in being 
one of the major killer diseases of mankind. The morbidity and mortality arising from this 
particular tumour is vast. This study done in our institution is a step towards understanding the 
behavior of this disease in the current scenario. 
             Gastric carcinoma is one of the malignanies to present in an advanced stage in a majority 
of cases. This is mainly attributed to the non specific symptoms accompanying it. This delays the 
timely diagnosis, which further delays the treatment.  
               Thanjavur Medical college, caters to the health care needs of  a mixed population of 
urban and semi urban people.This study documents the details regarding the incidence, age 
distribution, sex ratio, percentage of malignant lesions, predominant site, histological type , 
Tumour grade, extent of serosal invasion and nodal metastasis of the cases of gastric carcinoma 
diagnosed and treated here. 
             In this modern era, therapies are tailor made to suit the needs of the individual patient. 
Concepts of targeting  the molecular basis of the disease in gaining popularity. In this study two 
such markers were chosen. . Ki 67 is a proliferation marker. Its percentage of expression throws 
light in the aggressiveness of the tumour. HER2neu is a marker which is gaining importance in 
gastric cancer. Documentation of its level of expression in gastric carcinoma helps in using 
Trastuzumab, a monoclonal antibody against the HER2 receptor. This could be useful in patients 
who often presents in an advanced inoperable stage of the disease. 
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APPENDIX I 
 
HEMATOXYLIN AND EOSIN STAIN 
Preparation of solution : 
HARRIS HEMATOXYLIN 
 Distilled water             :1000ml 
 Ammonium alum         : 100g 
 Absolute ethyl alcohol  : 50 ml 
 Mercuric oxide              :2.5g 
 100g of ammonium alum is dissolved in 1000 ml of distilled water by heating at 600 C. 
add solution of 5g of hematoxylin in 50 ml of ethyl alcohol and bring rapidly to boil. 
When it begins to boil remove from flame and add 2.5 g of mercuric oxide. Mix by 
swirling gently. 
EOSIN STAIN 
 Eosin Y                       : 1 g. 
 Distilled water            : 20 ml 
 95% ethanol                : 80 ml 
 Glacial acetic acid       : 0.2 ml 
 Dissolve 1g of eosin Y in 20 ml of water, then add 80 ml of 95% ethyl alcohol and 0.2 ml 
of glacial acetic acid. 
 
 
 
 
 
Procedure : 
1. Bring the sections to water 
2. Dip in Harris hematoxylin for 15 minutes. 
3. Rinse in tap water. 
4. Differentiate in 1% acid alcohol- 3-4 quick dips. 
5. Wash in tap water briefly. 
6. Dip in ammonia water or saturated lithium carbonate until the sections are blue. 
7. Wash in running tap water for 10 -20 minutes. 
8. Stain with eosin for 15 seconds to 2 minutes depending upon the age of eosin and the 
depth of counter stain. 
9. Rinse in tap water. 
10. Dip in 95% alcohol. 
11. 3 changes in absolute alcohol. 
12. Xylene – 2 changes. 
13. Mount in DPX mountant. 
 
 
 
 
 
 
 
 
 
APPENDIX II 
PERIODIC ACID SCHIFF TECHNIQUE 
Solutions required 
a) 0.5% periodic acid 
b) Mayer’s haemalum 
c) Sulphorous acid 
    Sodium metabisulphite 10% 6 ml 
    N/10 Hydrochroric acid 10% 5 ml 
     Distilled water 100 ml 
d)  Schiffs Reagent 
   Basic Fuschin 1 gm 
   Sodium metabisulphite, anhydrous 1 gm 
   Distilled water 200 ml 
  N/10 Hydrochloric acid 20 ml 
Boil the distilled water, add the basic fuschin. Stir and cool to 500 C. Filter and add hydrochloric 
acid, cool to 250 C and add Sodium metabisulphite. The solution becomes ready for use when it 
becomes nearly colourless. This process may take upto two days in the dark. (Alternatively 
activated charcoal may be added to the solution, shaken and filtered). When the solution 
becomes discoloured it should be discarded. 
Technique 
1) Bring the sections to water. 
2) Periodic acid 0.5% for 5 minutes 
3) Rinse in distilled water 
4) Schiff’s reagent 15 minutes 
5) Rinse in three fresh changes of Sulphorous acid 2 minutes in each change for 6 minutes. 
6) Wash in running tap water each change 5 minutes 
7) Counter stain in Mayer’s haemalum 30 seconds 
8) Wash in running tap water 5 minutes 
9) Dehydrate, clear and mount 
Results 
Neutral mucin – Magenta, Nucleus – blue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX III 
IMMUNOHISTOCHEMISTRY 
PREPARATION OF SOLUTIONS: 
CITRATE BUFFER SOLUTION- ANTIGEN RETRIVAL SOLUTION 
Trisodium citrate                    : 2.94 gms 
1 N Hydrochloric acid            : 5 ml 
Required pH is 6.0, that is obtained by titration with 1N HCl. 
TRIS BUFFER SALINE (TBS) – WASH BUFFER 
Sodium chloride                      : 8 gms 
Tris (hydroxymethylamine)    : 0.605 gms 
1 N Hydrochloric acid            : 4 ml 
Distilled water                        : 1 litre 
Required pH is 7.6, that is obtained by titration with 1N HCl. 
PREPARATION OF CHROME ALUM COATED SLIDES 
Potassium dichromate            : 50 mgs 
Gelatin                                    : 300 mgs. 
Distilled water                        : 100 ml. 
Potassium dichromate is added to distilled water and then boiled to 600 C. gelatin is then added 
slowly to it. Glass slides are then dipped in this solution and dried overnight. 
After taking the required sections into the coated slides, it is baked overnight at 450  C in the 
autoclave. The slides are used for the procedure the next day. 
 
 
 
ANTIGEN RETRIVAL: 
The slides are arranged in a metal rack and placed in citrate buffer in a pressure cooker and 
allowed to boil up to three whistles. 
PROCEDURE : 
 Dewax the sections in xylene (15 minutes each, 2 changes) and then in decreasing grades 
of alcohol then finally bring the sections to running tap water followed by distilled water. 
 Antigen retrival using TBS by pressure cooker method. 
 Cool to room temperature in running tap water for 20 minutes. 
 Wash in TBS – 2 changes for five minutes each. 
 Drain and cover the tissues sections with power block for 15 minutes. 
 Drain and blot the excess power block. 
 Cover the sections with primary antibody for 90 minutes. 
 Wash in TBS – 2 changes for 5 minutes each. 
 Drain and cover the tissue sections with secondary antibody (HRP- Horse raddish 
peroxidase) for 30 minutes 
 Wash in TBS -2 changes for 5 minutes each. 
 Drain and cover the tissue sections with DAB (Diamino Benzidine) substrate buffer for 
5- 10 minutes.( depending on the time suggested in the supplied kit.) 
 Wash in distilled water, counter stained with hematoxylin, clear in xylene and mount 
with DPX. 
 
 
 
 
APPENDIX  –IV 
 
TNM STAGING SCHEME FOR GASTRIC CARCINOMA 
 
PRIMARY TUMOUR (T) 
TX Primary tumour cannot be assesed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ: intra epithelial tumour without invasion into lamina propria 
T1 Tumour invades lamina propria, muscularis mucosae or submucosa 
 
T1a Tumour invades lamina propria or muscularis mucosae 
T1b Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour penetrates sub serosal connective tissue without invasion of visceral peritoneum or 
adjacent structures 
T4 Tumour invades serosa(visceral peritoneum) or adjacent structures 
T4a Tumour invades serosa (visceral peritoneum) 
T4b Tumour invades adjacent structures 
REGIONAL LYMPH NODES (N) 
NX Regional lymphnodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-2 regional lymph nodes 
N2 Metastasis in 3-6 regional lymph nodes 
N3 Metastasis in 7 or more regional lymph nodes 
N3a Metastasis in 7-15 lymph nodes 
N3b Metastasis in 16 or more regional lymph nodes 
DISTANT METASTASIS (M) 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 
 
STAGE GROUPING FOR GASTRIC CARCINOMA 
 
 
Stage 0 Tis N0 M0 
Stage IA T1 N0 M0 
Stage IB T2 N0 M0 
 T1 N1 M0 
Stage IIA T3 N0 M0 
 T2 N1 M0 
 T1 N2 M0 
Stage IIB T4a N0 M0 
 T3 N1 M0 
 T2 N2 M0 
 T1 N3 M0 
Stage IIIA T4a N1 M0 
 T3 N2 M0 
 T2 N3 M0 
Stage IIIB T4b N0 M0 
 T4b N1 M0 
 T4a N2 M0 
 T3 N3 M0 
Stage IIIC T4b N2 M0 
 T4b N3 M0 
 T4a N3 M0 
Stage IV Any T Any N M1 
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